| 1 | N | Y | Y | Nimodipine
 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit | 0.75000 | Nitrendipine
 | 0.57786 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 2 | N | N | N | Metoclopramide
 | CHRNA5: cholinergic receptor, nicotinic, alpha 5 | 0.20000 | Galantamine hydrobromide
 | 0.44323 | CHRNA2 |
| 3 | Y | Y | N | Nicotine
 | CHRNA4: cholinergic receptor, nicotinic, alpha 4 | 0.40909 | Phencyclidine hydrochloride
 | 0.52847 | CHRNA2 |
| 4 | N | N | N | Proparacaine hydrochloride
 | KCNK5: potassium channel, subfamily K, member 5 | 0.66667 | Procaine hydrochloride
 | 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 5 | N | N | Y | Benzocaine
 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.57895 | Procaine hydrochloride
| 0.60410 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 6 | N | N | N | Riluzole
 | GRIK2: glutamate receptor, ionotropic, kainate 2 | 0 | Kainic acid hydrate
 | 0.81064 | GRIK3: glutamate receptor, ionotropic, kainate 3 |
| 7 | N | N | N | Diazoxide
 | ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 | 0.17500 | Verapamil
 | 0.68192 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 8 | N | N | N | Procainamide hydrochloride
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.71429 | Procaine hydrochloride
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 9 | N | N | N | Propafenone hydrochloride
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.45714 | Disopyramide
 | 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 10 | N | N | N | Carbachol
 | CHRNA1: cholinergic receptor, nicotinic, alpha 1 (muscle) | 0.35000 | Hexamethonium bromide
 | 0.46023 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 11 | N | Y | Y | Zonisamide
 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.36364 | Lamotrigine
 | 0.60410 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 12 | N | N | Y | Gallopamil hydrochloride
 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit | 0.86486 | Verapamil
| 0.56053 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 13 | N | N | N | Sevoflurane
 | GABRR2 | 0.041667 | Propofol
 | 0.68315 | GABRR1: gamma-aminobutyric acid (GABA) receptor, rho 1 |
| 14 | N | N | N | Isradipine
 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | 0.73333 | Felodipine
 | 0.28502 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 15 | N | N | N | Carbachol
| CHRNA7: cholinergic receptor, nicotinic, alpha 7 | 0.35000 | Hexamethonium bromide
| 0.35558 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 16 | N | N | Y | Diltiazem malate
 | CACNA1D: calcium channel, voltage-dependent, L type, alpha 1D subunit | 0.35791 | Amlodipine maleate
 | 0.64082 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 17 | N | N | N | Trifluoperazine hydrochloride
 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.87879 | Fluphenazine hydrochloride
 | 0.62986 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 18 | N | N | Y | Diltiazem hydrochloride
 | CACNA1D: calcium channel, voltage-dependent, L type, alpha 1D subunit | 0.40425 | Nicardipine hydrochloride
 | 0.64082 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 19 | N | N | N | Haloperidol
 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.30303 | Ketamine hydrochloride
 | 0.44349 | GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B |
| 20 | Y | N | N | Clozapine
 | HTR3C | 0.37143 | Ondansetron hydrochloride hydrate
 | 0.73813 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 21 | N | N | N | Propofol
| GLRA3 | 0.20690 | Tropisetron hydrochloride
 | 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 22 | N | N | N | Mexiletine hydrochloride
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.52381 | Lidocaine hydrochloride
 | 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 23 | N | N | N | Procainamide hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.71429 | Procaine hydrochloride
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 24 | N | N | N | Pentobarbital
 | CHRNA1: cholinergic receptor, nicotinic, alpha 1 (muscle) | 0.16129 | Metoclopramide
| 0.46023 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 25 | N | N | N | Diazepam
 | GLRA3 | 0.35484 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 26 | Y | N | N | Sumatriptan
 | HTR3C | 0.28000 | Dopamine hydrochloride
 | 0.73813 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 27 | N | N | N | Paramethadione
 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.75000 | Trimethadione
 | 0.44753 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 28 | N | N | N | Pindolol
 | HTR3C | 0.27273 | Granisetron hydrochloride
 | 0.73813 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 29 | N | N | N | Nimodipine
| CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 | 0.75000 | Nitrendipine
| 0.19447 | CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 |
| 30 | N | N | N | Isoflurane
 | GLRA2: glycine receptor, alpha 2 | 0.57143 | Sevoflurane
| 0.76918 | GLRA1: glycine receptor, alpha 1 |
| 31 | N | Y | Y | Verapamil hydrochloride
 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit | 0.97059 | Verapamil
| 0.56053 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 32 | N | N | N | Carbachol
| CHRNA5: cholinergic receptor, nicotinic, alpha 5 | 0.35000 | Hexamethonium bromide
| 0.44323 | CHRNA2 |
| 33 | Y | N | N | Nicotine
| CHRNA1: cholinergic receptor, nicotinic, alpha 1 (muscle) | 0.40909 | Phencyclidine hydrochloride
| 0.46023 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 34 | N | N | N | Tocainide hydrochloride
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.68421 | Prilocaine hydrochloride
 | 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 35 | N | N | N | Glyclopyramide
 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.73913 | Tolazamide
 | 0.39373 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 36 | N | N | N | Gliclazide
 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.79167 | Tolazamide
| 0.39373 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 37 | N | N | N | Trifluoperazine maleate
 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.74468 | Fluphenazine maleate
 | 0.62986 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 38 | N | N | N | Verapamil
| KCNK2: potassium channel, subfamily K, member 2 | 0.40909 | Dofetilide
 | 0.51272 | KCNK10: potassium channel, subfamily K, member 10 |
| 39 | N | N | N | Verapamil
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.12245 | Cocaine
 | 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 40 | N | N | N | Encainide hydrochloride
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.53333 | Mepivacaine hydrochloride
 | 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 41 | N | N | N | Verapamil
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.29412 | Glyburide
 | 0.68192 | ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 |
| 42 | N | N | N | Encainide hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.53333 | Mepivacaine hydrochloride
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 43 | N | N | N | Halothane
 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.66667 | Methoxyflurane
 | 0.048992 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 44 | N | N | N | Moricizine hydrochloride
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.43243 | Dyclonine hydrochloride
 | 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 45 | N | N | N | Felbamate
 | GLRA3 | 0.25806 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 46 | N | N | N | Tocainide hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.68421 | Prilocaine hydrochloride
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 47 | N | N | N | Amoxapine
 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.55556 | Mazindol
 | 0.68182 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 48 | N | N | N | Nimodipine
| CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | 0.75000 | Nitrendipine
| 0.28399 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 49 | N | N | N | Flecainide acetate
 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 | 0.25532 | Quinine hydrochloride hydrate
 | 0.66887 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 50 | Y | Y | N | Nicotine
| CHRNA7: cholinergic receptor, nicotinic, alpha 7 | 0.40909 | Phencyclidine hydrochloride
| 0.35558 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 51 | N | N | Y | Gallopamil hydrochloride
| CACNA1D: calcium channel, voltage-dependent, L type, alpha 1D subunit | 0.86486 | Verapamil
| 0.64082 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 52 | N | N | N | Isoflurane
| GLRB | 0.57143 | Sevoflurane
| 0.38089 | GLRA1: glycine receptor, alpha 1 |
| 53 | N | Y | N | Pentobarbital
| CHRNA7: cholinergic receptor, nicotinic, alpha 7 | 0.16129 | Metoclopramide
| 0.35558 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 54 | Y | N | Y | Granisetron
 | HTR3B: 5-hydroxytryptamine (serotonin) receptor 3B | 0.95833 | Granisetron hydrochloride
| 0.40524 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 55 | N | N | N | Trimethadione
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.75000 | Paramethadione
| 0.44753 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 56 | Y | N | Y | Metoclopramide
| HTR3C | 0.28000 | Dopamine hydrochloride
| 0.73813 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 57 | N | N | N | Fluphenazine maleate
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.74468 | Trifluoperazine maleate
| 0.62986 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 58 | N | N | N | Fluphenazine hydrochloride
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.87879 | Trifluoperazine hydrochloride
| 0.62986 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 59 | N | N | N | Caffeine
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.93333 | Caffeine hydrate
 | 0.014488 | P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 |
| 60 | N | N | N | Acetohexamide
 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.72000 | Tolazamide
| 0.39373 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 61 | N | N | N | Verapamil
| KCNK12: potassium channel, subfamily K, member 12 | 0.052632 | Halothane
| 0.61540 | KCNK13: potassium channel, subfamily K, member 13 |
| 62 | N | N | N | Sevoflurane
| GLRA3 | 0.030303 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 63 | N | N | N | Pentobarbital
| CHRNA5: cholinergic receptor, nicotinic, alpha 5 | 0.16000 | Mecamylamine hydrochloride
 | 0.44323 | CHRNA2 |
| 64 | N | N | N | Diazoxide
| KCNK2: potassium channel, subfamily K, member 2 | 0.22857 | Dofetilide
| 0.51272 | KCNK10: potassium channel, subfamily K, member 10 |
| 65 | N | N | N | Amiloride hydrochloride
 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.14286 | Zonisamide
| 0.47136 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 66 | N | Y | N | Trimipramine
 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.35484 | Mazindol
| 0.68182 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 67 | N | N | N | Flecainide acetate
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.38461 | Dyclonine hydrochloride
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 68 | N | N | N | Dantrolene
 | RYR3 | 0.31250 | Phenytoin
 | 0.66763 | RYR1: ryanodine receptor 1 (skeletal) |
| 69 | N | N | N | Dantrolene
| RYR2: ryanodine receptor 2 (cardiac) | 0.31250 | Phenytoin
| 0.66507 | RYR1: ryanodine receptor 1 (skeletal) |
| 70 | N | N | N | Moricizine hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.43243 | Dyclonine hydrochloride
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 71 | N | N | N | Nortriptyline hydrochloride
 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.86957 | Amitriptyline hydrochloride
 | 0.62986 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 72 | Y | N | N | Clozapine
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.37143 | Ondansetron hydrochloride hydrate
| 0.50844 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 73 | Y | N | Y | Granisetron
| HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E | 0.95833 | Granisetron hydrochloride
| 0.31879 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 74 | N | N | N | Amiloride hydrochloride
| SCN4B | 0.26923 | Riluzole
| 0.025789 | ACCN1: amiloride-sensitive cation channel 1, neuronal |
| 75 | N | N | N | Mexiletine hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.52381 | Lidocaine hydrochloride
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 76 | N | N | N | Chlorpromazine hibenzate
 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.36364 | Dequalinium chloride
 | 0.63878 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 77 | N | N | N | Etomidate
 | GABRR2 | 0.36667 | Zaleplon
 | 0.68315 | GABRR1: gamma-aminobutyric acid (GABA) receptor, rho 1 |
| 78 | Y | N | N | Lamotrigine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.40909 | Riluzole
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 79 | N | Y | N | Alprazolam
 | GABRR2 | 0.68000 | Diazepam
| 0.68315 | GABRR1: gamma-aminobutyric acid (GABA) receptor, rho 1 |
| 80 | N | Y | N | Flurazepam
 | GABRR2 | 0.62069 | Diazepam
| 0.68315 | GABRR1: gamma-aminobutyric acid (GABA) receptor, rho 1 |
| 81 | N | Y | N | Nicotine
| CHRNA5: cholinergic receptor, nicotinic, alpha 5 | 0.40909 | Phencyclidine hydrochloride
| 0.44323 | CHRNA2 |
| 82 | Y | Y | N | Methylphenidate
 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.56000 | Cocaine
| 0.49354 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 83 | N | N | N | Amiloride hydrochloride
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.26923 | Riluzole
| 0.087772 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 84 | Y | N | N | Sumatriptan
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.28000 | Dopamine hydrochloride
| 0.50844 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 85 | Y | N | Y | Ondansetron
 | HTR3B: 5-hydroxytryptamine (serotonin) receptor 3B | 0.88000 | Ondansetron hydrochloride hydrate
| 0.40524 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 86 | N | N | N | Pindolol
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.27273 | Granisetron hydrochloride
| 0.50844 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 87 | Y | Y | Y | Mazindol
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.55556 | Amoxapine
| 0.49354 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 88 | N | N | N | Cyproheptadine hydrochloride
 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.37500 | Chlorpromazine hibenzate
| 0.62986 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 89 | N | N | N | Chlorpromazine phenolphthalinate
 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.30645 | Dequalinium chloride
| 0.63878 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 90 | N | N | N | Desipramine hydrochloride
 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.72000 | Amitriptyline hydrochloride
| 0.62986 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 91 | N | N | N | Quinidine gluconate
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.25532 | Levobupivacaine hydrochloride
 | 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 92 | N | N | N | Amiloride hydrochloride
| SCN1B: sodium channel, voltage-gated, type I, beta | 0.26923 | Riluzole
| 0.024163 | ACCN3: amiloride-sensitive cation channel 3 |
| 93 | N | N | N | Verapamil hydrochloride
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.97059 | Verapamil
| 0.66887 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 94 | N | N | N | Tropisetron hydrochloride
| GLRB | 0.35484 | Diazepam
| 0.39983 | GLRA3 |
| 95 | N | N | N | Amiloride hydrochloride
| SCN3B: sodium channel, voltage-gated, type III, beta | 0.26923 | Riluzole
| 0.024794 | ACCN1: amiloride-sensitive cation channel 1, neuronal |
| 96 | N | N | N | Bethanidine sulfate
 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.25714 | Phentermine
 | 0.68182 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 97 | N | N | N | Pentobarbital
| GABRR2 | 0.16000 | Propofol
| 0.68315 | GABRR1: gamma-aminobutyric acid (GABA) receptor, rho 1 |
| 98 | N | Y | Y | Zonisamide
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.36364 | Lamotrigine
| 0.87680 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 99 | N | N | N | Levetiracetam
 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.29412 | Ethosuximide
 | 0.48256 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 100 | N | N | N | Caffeine
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.93333 | Caffeine hydrate
| 0.021666 | P2RX4: purinergic receptor P2X, ligand-gated ion channel, 4 |
| 101 | N | N | N | Flecainide acetate
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.27778 | Quinidine gluconate
| 0.58884 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 102 | N | N | N | Amitriptyline hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.41935 | Fluoxetine
 | 0.63878 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 103 | N | N | N | Quinidine sulfate
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.20548 | Verapamil
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 104 | N | N | N | Diltiazem malate
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 0.33962 | Verapamil
| 0.59825 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 105 | N | N | N | Maprotiline
 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.41379 | Mazindol
| 0.68182 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 106 | Y | N | Y | Ondansetron
| HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E | 0.88000 | Ondansetron hydrochloride hydrate
| 0.31879 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 107 | N | N | N | Verapamil hydrochloride
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.97059 | Verapamil
| 0.66583 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 108 | N | N | N | Verapamil hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.97059 | Verapamil
| 0.53491 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 109 | N | Y | N | Midazolam
 | GABRR2 | 0.59259 | Diazepam
| 0.68315 | GABRR1: gamma-aminobutyric acid (GABA) receptor, rho 1 |
| 110 | N | N | N | Phenytoin
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.37500 | Dizocilpine maleate
 | 0.022827 | SCN4B |
| 111 | N | N | N | Verapamil
| GRIA3: glutamate receptor, ionotrophic, AMPA 3 | 0.20000 | Riluzole
| 0.026689 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 112 | Y | N | N | Sertraline
 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.57692 | Maprotiline
| 0.49354 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 113 | N | N | N | Diltiazem hydrochloride
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 0.39130 | Verapamil hydrochloride
| 0.59825 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 114 | N | N | N | Verapamil
| GRIA4: glutamate receptor, ionotrophic, AMPA 4 | 0.20000 | Riluzole
| 0.026577 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 115 | N | Y | Y | Verapamil hydrochloride
| CACNA1D: calcium channel, voltage-dependent, L type, alpha 1D subunit | 0.97059 | Verapamil
| 0.64082 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 116 | N | N | N | Paramethadione
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.40000 | Ethosuximide
| 0.47136 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 117 | N | N | N | Flecainide acetate
| KCNK5: potassium channel, subfamily K, member 5 | 0.38461 | Dyclonine hydrochloride
| 0.030801 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 118 | N | N | N | Trimethadione
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.33333 | Ethosuximide
| 0.48256 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 119 | N | N | N | Quinidine sulfate
| KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 | 1 | Quinine sulfate
 | 0.56382 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 120 | N | N | N | Diazoxide
| KCNK12: potassium channel, subfamily K, member 12 | 0.050000 | Halothane
| 0.61540 | KCNK13: potassium channel, subfamily K, member 13 |
| 121 | N | N | N | Gallopamil hydrochloride
| KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 | 0.89189 | Verapamil hydrochloride
| 0.021436 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 122 | N | N | N | Benoxinate hydrochloride
 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.80000 | Proparacaine hydrochloride
| 0.60410 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 123 | N | N | N | Isoflurane
| GABRR2 | 0.095238 | Propofol
| 0.68315 | GABRR1: gamma-aminobutyric acid (GABA) receptor, rho 1 |
| 124 | N | N | N | Dofetilide
| KCNH1: potassium voltage-gated channel, subfamily H (eag-related), member 1 | 0.40909 | Verapamil
| 0.74648 | KCNH5: potassium voltage-gated channel, subfamily H (eag-related), member 5 |
| 125 | N | N | N | Promethazine hydrochloride
 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.65385 | Amitriptyline hydrochloride
| 0.62986 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 126 | N | N | N | Levetiracetam
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.29412 | Ethosuximide
| 0.44753 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 127 | N | N | N | Gabapentin
 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.26316 | Levetiracetam
| 0.83065 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 128 | Y | N | N | Verapamil
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.34091 | Propafenone hydrochloride
| 0.86296 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 129 | N | N | N | Mibefradil dihydrochloride
 | CACNA1B: calcium channel, voltage-dependent, N type, alpha 1B subunit | 0.44898 | Verapamil
| 0.58498 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 130 | N | N | N | Guanadrel sulfate
 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.083333 | Methylphenidate
| 0.68182 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 131 | N | N | N | Dequalinium chloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.42500 | Desipramine hydrochloride
| 0.55275 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 132 | N | N | N | Dequalinium chloride
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.41463 | Amitriptyline hydrochloride
| 0.63878 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 133 | N | N | N | Carbachol
| CHRND: cholinergic receptor, nicotinic, delta | 0.29167 | Metoclopramide
| 0.42466 | CHRNE: cholinergic receptor, nicotinic, epsilon |
| 134 | N | N | N | Promethazine teoclate
 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.43590 | Amitriptyline hydrochloride
| 0.62986 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 135 | N | N | N | Guanethidine sulfate
 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.086957 | Methylphenidate
| 0.68182 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 136 | N | N | N | Ibutilide fumarate
 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit | 0.30667 | Diltiazem malate
| 0.57786 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 137 | N | N | N | Zaleplon
| GLRB | 0.30303 | Diazepam
| 0.29609 | GABRB1 |
| 138 | N | N | N | Verapamil
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.34091 | Propafenone hydrochloride
| 0.75410 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 139 | N | N | N | Mibefradil dihydrochloride
| CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit | 0.46939 | Verapamil hydrochloride
| 0.29326 | CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit |
| 140 | N | N | N | Maprotiline
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.57692 | Sertraline
| 0.49354 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 141 | N | N | Y | Mirtazapine
 | HTR3B: 5-hydroxytryptamine (serotonin) receptor 3B | 0.53571 | Clozapine
| 0.40524 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 142 | N | N | Y | Prilocaine
 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.94118 | Prilocaine hydrochloride
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 143 | N | N | Y | Diazoxide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.32000 | Glyclopyramide
| 0.66902 | KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 |
| 144 | N | N | N | Verapamil
| ACCN1: amiloride-sensitive cation channel 1, neuronal | 0.085106 | Amiloride hydrochloride
| 0.48895 | ACCN3: amiloride-sensitive cation channel 3 |
| 145 | Y | N | N | Verapamil
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.34091 | Propafenone hydrochloride
| 0.72659 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 146 | N | N | Y | Disopyramide
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.45714 | Propafenone hydrochloride
| 0.83065 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 147 | N | Y | Y | Zonisamide
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.36364 | Lamotrigine
| 0.76982 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 148 | N | N | N | Methylphenidate
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.56000 | Cocaine
| 0.44420 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
| 149 | N | N | N | Flecainide acetate
| KCNA6: potassium voltage-gated channel, shaker-related subfamily, member 6 | 0.20370 | Verapamil
| 0.60832 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 150 | N | N | N | Lamotrigine
| KCNK5: potassium channel, subfamily K, member 5 | 0.30435 | Diazoxide
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 151 | N | N | N | Verapamil
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.29167 | Ibutilide fumarate
| 0.66902 | KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 |
| 152 | Y | N | Y | Benzocaine
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.57895 | Procaine hydrochloride
| 0.83065 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 153 | N | N | N | Verapamil
| ACCN2: amiloride-sensitive cation channel 2, neuronal | 0.085106 | Amiloride hydrochloride
| 0.47336 | ACCN3: amiloride-sensitive cation channel 3 |
| 154 | N | N | N | Cocaine
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0.11111 | Proline
 | 0.42834 | SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 |
| 155 | N | N | N | Glimepiride
 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.58537 | Glipizide
 | 0.39373 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 156 | Y | N | N | Verapamil
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.34091 | Propafenone hydrochloride
| 0.83065 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 157 | Y | N | N | Tubocurarine chloride
 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.28169 | Chlorpromazine hibenzate
| 0.62986 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 158 | N | N | N | Ethotoin
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.72222 | Primidone
 | 0.0092349 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 159 | N | N | N | Gallopamil hydrochloride
| CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | 0.86486 | Verapamil
| 0.28502 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 160 | N | N | N | Pentobarbital
| CHRND: cholinergic receptor, nicotinic, delta | 0.16129 | Metoclopramide
| 0.42466 | CHRNE: cholinergic receptor, nicotinic, epsilon |
| 161 | N | N | N | Carbachol
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.29167 | Metoclopramide
| 0.37214 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 162 | N | N | N | Isradipine
| CACNA2D3: calcium channel, voltage-dependent, alpha 2/delta subunit 3 | 0.66667 | Nisoldipine
 | 0.61055 | CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 |
| 163 | N | N | N | Gallopamil hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.89189 | Verapamil hydrochloride
| 0.012103 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 164 | N | N | N | Diazoxide
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.38095 | Riluzole
| 0.19653 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 165 | N | Y | N | Phentermine
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.32000 | Cocaine
| 0.49354 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 166 | Y | N | N | Nicotine
| CHRND: cholinergic receptor, nicotinic, delta | 0.14286 | Metoclopramide
| 0.42466 | CHRNE: cholinergic receptor, nicotinic, epsilon |
| 167 | Y | Y | N | Paroxetine
 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.48387 | Amoxapine
| 0.49354 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 168 | N | N | N | Etomidate
| GLRA1: glycine receptor, alpha 1 | 0.40000 | Felbamate
| 0.32784 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 169 | N | N | N | Riluzole
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.40909 | Lamotrigine
| 0.83065 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 170 | N | N | Y | Zonisamide
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.36364 | Lamotrigine
| 0.75242 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 171 | N | N | N | Verapamil hydrochloride
| KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.97059 | Verapamil
| 0.63973 | KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 |
| 172 | N | N | Y | Tolbutamide
 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.56000 | Tolazamide
| 0.39373 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 173 | N | N | N | Isradipine
| CACNB1: calcium channel, voltage-dependent, beta 1 subunit | 0.66667 | Nisoldipine
| 0.56271 | CACNB2: calcium channel, voltage-dependent, beta 2 subunit |
| 174 | N | N | N | Ibutilide fumarate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.29167 | Verapamil
| 0.56271 | CACNB1: calcium channel, voltage-dependent, beta 1 subunit |
| 175 | N | N | N | Gallopamil hydrochloride
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 0.89189 | Verapamil hydrochloride
| 0.022438 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 176 | N | N | N | Doxorubicin hydrochloride
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.23729 | Glyburide
| 0.0043818 | RYR2: ryanodine receptor 2 (cardiac) |
| 177 | N | N | N | Pentobarbital
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.16129 | Metoclopramide
| 0.37214 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 178 | N | N | N | Diltiazem hydrochloride
| KCNA6: potassium voltage-gated channel, shaker-related subfamily, member 6 | 0.36956 | Verapamil
| 0.60832 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 179 | N | N | N | Phenacemide
 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.42105 | Tocainide
 | 0.60301 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 180 | Y | N | N | Nicotine
| HTR3B: 5-hydroxytryptamine (serotonin) receptor 3B | 0.36000 | Tropisetron hydrochloride
| 0.40524 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 181 | Y | N | Y | Carbamazepine
 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.40000 | Moricizine hydrochloride
| 0.83065 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 182 | N | N | N | Diltiazem hydrochloride
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.39130 | Verapamil hydrochloride
| 0.58819 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 183 | N | N | N | Diltiazem malate
| KCNA6: potassium voltage-gated channel, shaker-related subfamily, member 6 | 0.33962 | Verapamil
| 0.60832 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 184 | N | N | N | Flecainide acetate
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.28302 | Ketoconazole
 | 0.58819 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 185 | Y | N | N | Nicotine
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.14286 | Metoclopramide
| 0.37214 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 186 | N | N | N | Verapamil hydrochloride
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.97059 | Verapamil
| 0.54817 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 187 | N | N | N | Quinine sulfate
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 1 | Quinidine sulfate
| 0.56382 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 188 | N | N | N | Diltiazem malate
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.33962 | Verapamil
| 0.58884 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 189 | N | N | N | Kainic acid hydrate
| GRID2: glutamate receptor, ionotropic, delta 2 | 0 | Riluzole
| 0.20292 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 190 | N | N | N | Furosemide
 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.51613 | Benzthiazide
 | 0.011447 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 191 | N | N | N | Mibefradil dihydrochloride
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.46939 | Verapamil hydrochloride
| 0.28734 | CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit |
| 192 | N | N | N | Cocaine
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0.11111 | Proline
| 0.38828 | SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 |
| 193 | N | N | N | Trifluoperazine hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.51429 | Fluoxetine hydrochloride
 | 0.63878 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 194 | N | N | N | Verapamil
| GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.20000 | Riluzole
| 0.027448 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 195 | N | N | N | Diltiazem hydrochloride
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.40425 | Nicardipine hydrochloride
| 0.58884 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 196 | N | Y | N | Isradipine
| CACNA2D2: calcium channel, voltage-dependent, alpha 2/delta subunit 2 | 0.66667 | Nisoldipine
| 0.52208 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
| 197 | N | N | N | Cyproheptadine hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.39317 | Tubocurarine chloride
| 0.63878 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 198 | N | N | Y | Topiramate
 | GRIK3: glutamate receptor, ionotropic, kainate 3 | 0.15152 | Kainic acid hydrate
| 0.72331 | GRIK1: glutamate receptor, ionotropic, kainate 1 |
| 199 | N | N | N | Profenamine hydrochloride
 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.76000 | Promethazine hydrochloride
| 0.013549 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 200 | N | N | N | Gabapentin
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.096774 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 201 | N | N | N | Gabapentin
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.25926 | Dyclonine hydrochloride
| 0.86296 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 202 | N | N | N | Diltiazem malate
| CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | 0.38182 | Mibefradil dihydrochloride
| 0.28502 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 203 | N | N | N | Quinine sulfate
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 1 | Quinidine sulfate
| 0.53491 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 204 | Y | N | Y | Granisetron
| HTR3C | 0.95833 | Granisetron hydrochloride
| 0.31377 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 205 | N | N | N | Isradipine
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.66667 | Nisoldipine
| 0.29326 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 206 | N | N | N | Doxorubicin hydrochloride
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.24624 | Ketoconazole
| 0.0071212 | RYR2: ryanodine receptor 2 (cardiac) |
| 207 | N | N | N | Phenytoin
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.17143 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 208 | N | N | N | Streptomycin sulfate
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.066667 | Glyburide
| 0.0043818 | RYR2: ryanodine receptor 2 (cardiac) |
| 209 | N | N | N | Quinidine gluconate
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.31579 | Diltiazem malate
| 0.58845 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 210 | N | N | N | Verapamil
| MCOLN1: mucolipin 1 | 0.085106 | Amiloride hydrochloride
| 0.032255 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 211 | N | Y | N | Magnesium sulfate
 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit | 0.062500 | Amlodipine besylate
 | 0.57786 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 212 | Y | N | N | Riluzole
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.40909 | Lamotrigine
| 0.86296 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 213 | N | N | Y | Acetohexamide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.61765 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 214 | N | N | Y | Glyburide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.77778 | Glipizide
| 0.39373 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 215 | N | N | N | Nimodipine
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.75000 | Nitrendipine
| 0.12954 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 216 | N | N | N | Zaleplon
| GLRA2: glycine receptor, alpha 2 | 0.30303 | Diazepam
| 0.32569 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 217 | N | N | N | Haloperidol
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.42492 | Thioridazine hydrochloride
 | 0.015023 | GRIN2C: glutamate receptor, ionotropic, N-methyl D-aspartate 2C |
| 218 | N | N | N | Diltiazem malate
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.33962 | Verapamil
| 0.58819 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 219 | N | N | N | Halothane
| RYR2: ryanodine receptor 2 (cardiac) | 0.078947 | Pimozide
 | 0.021708 | ITPR3: inositol 1,4,5-trisphosphate receptor, type 3 |
| 220 | Y | N | Y | Metoclopramide
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.28000 | Dopamine hydrochloride
| 0.50844 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 221 | N | N | Y | Dibucaine
 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.48276 | Procainamide hydrochloride
| 0.58238 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 222 | N | N | N | Verapamil
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.085106 | Amiloride hydrochloride
| 0.027859 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
| 223 | N | N | N | Carbachol
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.29167 | Metoclopramide
| 0.26265 | CHRNA10 |
| 224 | N | N | N | Halothane
| RYR3 | 0.078947 | Pimozide
| 0.021825 | ITPR3: inositol 1,4,5-trisphosphate receptor, type 3 |
| 225 | N | N | N | Riluzole
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.12121 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 226 | N | N | Y | Mirtazapine
| HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E | 0.53571 | Clozapine
| 0.31879 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 227 | N | N | Y | Cocaine
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.36000 | Benzocaine
| 0.58238 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 228 | N | N | N | Riluzole
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.45833 | Hydroflumethiazide
 | 0.016547 | SCN1B: sodium channel, voltage-gated, type I, beta |
| 229 | N | N | N | Ethosuximide
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.47059 | Butabarbital
 | 0.011438 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 230 | N | N | N | Gallopamil hydrochloride
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.89189 | Verapamil hydrochloride
| 0.022185 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 231 | N | N | N | Mibefradil dihydrochloride
| CACNA1D: calcium channel, voltage-dependent, L type, alpha 1D subunit | 0.44898 | Verapamil
| 0.27185 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 232 | N | N | N | Ibutilide fumarate
| KCNH5: potassium voltage-gated channel, subfamily H (eag-related), member 5 | 0.41270 | Dofetilide
| 0.27171 | KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 |
| 233 | N | N | N | Ibutilide fumarate
| CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit | 0.30667 | Diltiazem malate
| 0.56053 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 234 | N | N | N | Dofetilide
| KCNH7: potassium voltage-gated channel, subfamily H (eag-related), member 7 | 0.41270 | Ibutilide fumarate
| 0.52729 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 235 | N | N | Y | Topiramate
| GRIK2: glutamate receptor, ionotropic, kainate 2 | 0.15152 | Kainic acid hydrate
| 0.76835 | GRIK1: glutamate receptor, ionotropic, kainate 1 |
| 236 | N | N | N | Dofetilide
| KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 | 0.41270 | Ibutilide fumarate
| 0.50037 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 237 | N | N | N | Quinine sulfate
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 1 | Quinidine sulfate
| 0.54817 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 238 | N | N | N | Nimodipine
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.75000 | Nitrendipine
| 0.11063 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 239 | N | N | N | Propafenone hydrochloride
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 0.45000 | Amiodarone hydrochloride
 | 0.51877 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 240 | N | N | N | Granisetron hydrochloride
| GLRA3 | 0.53333 | Tropisetron hydrochloride
| 0.095753 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 241 | N | N | N | Etomidate
| GLRB | 0.40000 | Felbamate
| 0.29609 | GABRB1 |
| 242 | N | N | N | Penfluridol
 | CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.64729 | Pimozide
| 0.12631 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 243 | Y | N | Y | Granisetron
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.95833 | Granisetron hydrochloride
| 0.16111 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 244 | N | N | N | Phentermine
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.32000 | Cocaine
| 0.44420 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
| 245 | N | N | N | Diltiazem hydrochloride
| CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | 0.44681 | Mibefradil dihydrochloride
| 0.28502 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 246 | N | N | N | Trimipramine
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.72000 | Promethazine hydrochloride
| 0.017087 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 247 | Y | Y | Y | Phenytoin
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.36364 | Propafenone hydrochloride
| 0.83065 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 248 | N | N | N | Felodipine
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.75862 | Nitrendipine
| 0.018083 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 249 | N | N | N | Magnesium sulfate
| CACNA1D: calcium channel, voltage-dependent, L type, alpha 1D subunit | 0.062500 | Amlodipine besylate
| 0.64082 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 250 | N | N | N | Mibefradil dihydrochloride
| CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit | 0.44898 | Verapamil
| 0.27364 | CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit |
| 251 | N | N | N | Verapamil hydrochloride
| KCNA6: potassium voltage-gated channel, shaker-related subfamily, member 6 | 0.97059 | Verapamil
| 0.57211 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 252 | N | N | N | Gabapentin
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.25926 | Dyclonine hydrochloride
| 0.75410 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 253 | N | N | N | Etomidate
| GLRA2: glycine receptor, alpha 2 | 0.40000 | Felbamate
| 0.32569 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 254 | N | N | N | Levobupivacaine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.95652 | Bupivacaine hydrochloride
 | 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 255 | N | N | N | Kainic acid hydrate
| GRIA3: glutamate receptor, ionotrophic, AMPA 3 | 0.034483 | Diazoxide
| 0.35489 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 256 | N | N | N | Verapamil
| CLCN2: chloride channel 2 | 0.11111 | Lubiprostone
 | 0.022598 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 257 | N | N | N | Nimodipine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.75000 | Nitrendipine
| 0.10257 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 258 | N | N | N | Quinidine sulfate
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 1 | Quinine sulfate
| 0.20403 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 259 | N | N | Y | Topiramate
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.20000 | Mexiletine hydrochloride
| 0.87680 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 260 | N | N | N | Levetiracetam
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.30769 | Dyclonine hydrochloride
| 0.87680 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 261 | N | N | N | Riluzole
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.40909 | Lamotrigine
| 0.75410 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 262 | N | N | N | Verapamil
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.29412 | Glyburide
| 0.15287 | ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 |
| 263 | N | N | N | Kainic acid hydrate
| GRIA4: glutamate receptor, ionotrophic, AMPA 4 | 0.034483 | Diazoxide
| 0.34506 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 264 | N | N | N | Trifluoperazine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.64706 | Thioridazine hydrochloride
| 0.030674 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 265 | N | N | N | Gallopamil hydrochloride
| KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 | 0.89189 | Verapamil hydrochloride
| 0.022846 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 266 | N | N | N | Magnesium sulfate
| CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit | 0.062500 | Amlodipine besylate
| 0.56053 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 267 | Y | N | N | Nicotine
| HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E | 0.36000 | Tropisetron hydrochloride
| 0.31879 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 268 | N | N | N | Aminoglutethimide
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.57143 | Primidone
| 0.090264 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 269 | N | N | N | Felodipine
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.75862 | Nitrendipine
| 0.0092209 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 270 | N | N | N | Enflurane
 | GLRA2: glycine receptor, alpha 2 | 0.46667 | Sevoflurane
| 0.76918 | GLRA1: glycine receptor, alpha 1 |
| 271 | N | Y | N | Felodipine
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.75862 | Nitrendipine
| 0.017211 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 272 | N | N | N | Gabapentin
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.25926 | Dyclonine hydrochloride
| 0.72659 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 273 | Y | N | Y | Phenytoin
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.36364 | Propafenone hydrochloride
| 0.86296 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 274 | Y | N | Y | Dibucaine
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.48276 | Procainamide hydrochloride
| 0.60341 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 275 | N | N | N | Trifluoperazine maleate
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.34694 | Fluoxetine
| 0.63878 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 276 | Y | N | Y | Cocaine
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.36000 | Benzocaine
| 0.60341 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 277 | N | N | N | Nateglinide
 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.45161 | Gliclazide
| 0.39373 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 278 | N | N | N | Quinidine gluconate
| KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 | 0.60000 | Quinine hydrochloride hydrate
| 0.56382 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 279 | N | Y | Y | Glipizide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.77778 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 280 | N | N | N | Zaleplon
| GLRA1: glycine receptor, alpha 1 | 0.30303 | Diazepam
| 0.32784 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 281 | N | N | N | Streptomycin sulfate
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.075630 | Verapamil
| 0.0071212 | RYR2: ryanodine receptor 2 (cardiac) |
| 282 | N | Y | N | Verapamil hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.97059 | Verapamil
| 0.023050 | KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 |
| 283 | N | N | N | Riluzole
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.40909 | Lamotrigine
| 0.72659 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 284 | N | N | N | Pentobarbital
| GLRB | 0.16000 | Propofol
| 0.29609 | GABRB1 |
| 285 | N | N | N | Methoxyflurane
| GLRA2: glycine receptor, alpha 2 | 0.33333 | Sevoflurane
| 0.76918 | GLRA1: glycine receptor, alpha 1 |
| 286 | N | N | N | Dofetilide
| KCNK10: potassium channel, subfamily K, member 10 | 0.40909 | Verapamil
| 0.51272 | KCNK2: potassium channel, subfamily K, member 2 |
| 287 | N | N | N | Ibutilide fumarate
| CACNA1D: calcium channel, voltage-dependent, L type, alpha 1D subunit | 0.29167 | Verapamil
| 0.64082 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 288 | N | N | N | Propofol
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.22727 | Diazoxide
| 0.018959 | GLRA1: glycine receptor, alpha 1 |
| 289 | N | N | N | Butabarbital
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.82353 | Pentobarbital
| 0.090264 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 290 | N | N | N | Nicardipine hydrochloride
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.67568 | Nitrendipine
| 0.51802 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 291 | N | N | N | Thioridazine hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.56757 | Fluphenazine hydrochloride
| 0.024221 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 292 | N | N | N | Mazindol
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.20000 | Cocaine
| 0.44420 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
| 293 | N | N | N | Kainic acid hydrate
| GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.11111 | Cyclothiazide
 | 0.36035 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 294 | Y | N | N | Tubocurarine chloride
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.21311 | Letrozole
 | 0.44784 | CHRNA2 |
| 295 | N | N | N | Quinidine sulfate
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.20779 | Diltiazem malate
| 0.58845 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 296 | N | N | N | Aminoglutethimide
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.32000 | Pentobarbital
| 0.31850 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 297 | N | N | N | Felbamate
| GABRR2 | 0.20000 | Propofol
| 0.29902 | GLRA2: glycine receptor, alpha 2 |
| 298 | N | N | N | Metocurine iodide
 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.67619 | Tubocurarine chloride
| 0.018097 | CHRNA2 |
| 299 | N | N | N | Phenacemide
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.40000 | Tocainide hydrochloride
| 0.87680 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 300 | N | N | N | Ibutilide fumarate
| KCNH1: potassium voltage-gated channel, subfamily H (eag-related), member 1 | 0.29167 | Verapamil
| 0.28151 | KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 |
| 301 | N | N | N | Halothane
| RYR1: ryanodine receptor 1 (skeletal) | 0.078947 | Pimozide
| 0.021654 | ITPR1: inositol 1,4,5-trisphosphate receptor, type 1 |
| 302 | N | N | N | Caffeine hydrate
| P2RX4: purinergic receptor P2X, ligand-gated ion channel, 4 | 0.93333 | Caffeine
| 0.021666 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 303 | N | N | N | Nicardipine hydrochloride
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.67568 | Nitrendipine
| 0.019066 | KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 |
| 304 | N | Y | N | Verapamil hydrochloride
| CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | 0.97059 | Verapamil
| 0.28502 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 305 | N | N | Y | Phenytoin
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.36364 | Propafenone hydrochloride
| 0.75410 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 306 | N | N | N | Trimipramine
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.25714 | Cocaine
| 0.43128 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 307 | N | N | N | Ropivacaine hydrochloride
 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.87500 | Bupivacaine hydrochloride
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 308 | N | N | N | Exemestane
 | CHRNA2 | 0.27273 | Dextromethorphan
 | 0.44784 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 309 | N | N | N | Dextromethorphan
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.37037 | Methylphenidate
| 0.49354 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 310 | N | N | N | Ketamine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.38710 | Thioridazine hydrochloride
| 0.024001 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 311 | N | N | N | Caffeine hydrate
| P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 | 0.93333 | Caffeine
| 0.019059 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 312 | N | Y | N | Nimodipine
| CACNB1: calcium channel, voltage-dependent, beta 1 subunit | 0.75000 | Nitrendipine
| 0.56271 | CACNB2: calcium channel, voltage-dependent, beta 2 subunit |
| 313 | Y | N | N | Tubocurarine chloride
| GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 | 0.23975 | Midazolam
| 0.43368 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 314 | Y | N | Y | Ondansetron
| HTR3C | 0.88000 | Ondansetron hydrochloride hydrate
| 0.31377 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 315 | N | N | N | Amlodipine besylate
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.48837 | Nitrendipine
| 0.51802 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 316 | N | N | N | Caffeine hydrate
| P2RX3: purinergic receptor P2X, ligand-gated ion channel, 3 | 0.93333 | Caffeine
| 0.016400 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 317 | N | N | N | Caffeine hydrate
| P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 | 0.93333 | Caffeine
| 0.019642 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 318 | N | N | N | Caffeine hydrate
| P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 | 0.93333 | Caffeine
| 0.015356 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 319 | N | N | N | Quinine hydrochloride hydrate
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.60000 | Quinidine gluconate
| 0.53491 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 320 | N | N | Y | Oxcarbazepine
 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.76191 | Carbamazepine
| 0.58238 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 321 | N | N | N | Quinidine gluconate
| KCNK4: potassium channel, subfamily K, member 4 | 0.18644 | Verapamil
| 0.38351 | KCNK2: potassium channel, subfamily K, member 2 |
| 322 | N | N | N | Amoxapine
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.22222 | Cocaine
| 0.43128 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 323 | N | N | N | Oxcarbazepine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.76191 | Carbamazepine
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 324 | N | N | N | Ibutilide fumarate
| CACNA2D2: calcium channel, voltage-dependent, alpha 2/delta subunit 2 | 0.29167 | Verapamil
| 0.52208 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
| 325 | N | N | N | Halothane
| GLRA2: glycine receptor, alpha 2 | 0.46154 | Sevoflurane
| 0.76918 | GLRA1: glycine receptor, alpha 1 |
| 326 | N | Y | N | Quinidine gluconate
| KCNK1: potassium channel, subfamily K, member 1 | 0.21250 | Ibutilide fumarate
| 0.38862 | KCNK6: potassium channel, subfamily K, member 6 |
| 327 | N | N | N | Diazoxide
| GRIK5: glutamate receptor, ionotropic, kainate 5 | 0.38095 | Riluzole
| 0.29524 | GRIA3: glutamate receptor, ionotrophic, AMPA 3 |
| 328 | N | N | N | Desflurane
 | GLRA2: glycine receptor, alpha 2 | 0.57143 | Sevoflurane
| 0.76918 | GLRA1: glycine receptor, alpha 1 |
| 329 | N | N | N | Propofol
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.26471 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 330 | N | Y | Y | Glimepiride
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.55814 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 331 | N | N | N | Proline
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.11111 | Cocaine
| 0.42834 | SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 |
| 332 | N | N | Y | Mecamylamine hydrochloride
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.20690 | Exemestane
| 0.44784 | CHRNA2 |
| 333 | N | Y | N | Nicardipine hydrochloride
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.67568 | Nitrendipine
| 0.021060 | KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 |
| 334 | N | N | Y | Tocainide
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.93333 | Tocainide hydrochloride
| 0.60301 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 335 | N | N | N | Nicardipine hydrochloride
| CACNA1B: calcium channel, voltage-dependent, N type, alpha 1B subunit | 0.67568 | Nitrendipine
| 0.58498 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 336 | N | N | N | Magnesium sulfate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.027027 | Nifedipine
 | 0.19447 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
| 337 | N | N | N | Caffeine hydrate
| P2RX7: purinergic receptor P2X, ligand-gated ion channel, 7 | 0.93333 | Caffeine
| 0.013336 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 338 | N | N | N | Isradipine
| CACNA1B: calcium channel, voltage-dependent, N type, alpha 1B subunit | 0.66667 | Nisoldipine
| 0.29050 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 339 | N | N | N | Nimodipine
| CACNA2D3: calcium channel, voltage-dependent, alpha 2/delta subunit 3 | 0.75000 | Nitrendipine
| 0.61055 | CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 |
| 340 | N | N | N | Caffeine hydrate
| P2RX2: purinergic receptor P2X, ligand-gated ion channel, 2 | 0.93333 | Caffeine
| 0.017000 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 341 | N | N | N | Diazoxide
| GRIK4: glutamate receptor, ionotropic, kainate 4 | 0.38095 | Riluzole
| 0.29011 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
| 342 | N | N | N | Isradipine
| CACNB4: calcium channel, voltage-dependent, beta 4 subunit | 0.66667 | Nisoldipine
| 0.54913 | CACNB2: calcium channel, voltage-dependent, beta 2 subunit |
| 343 | N | N | N | Paramethadione
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.30435 | Methohexital
 | 0.011438 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 344 | N | N | N | Desflurane
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.23529 | Flecainide acetate
| 0.79208 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 345 | N | N | N | Maprotiline
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.68000 | Desipramine hydrochloride
| 0.017087 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 346 | N | Y | N | Amlodipine besylate
| CACNA1B: calcium channel, voltage-dependent, N type, alpha 1B subunit | 0.48837 | Nitrendipine
| 0.58498 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 347 | Y | N | Y | Phenytoin
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.36364 | Propafenone hydrochloride
| 0.72659 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 348 | N | N | N | Diazoxide
| GRIK3: glutamate receptor, ionotropic, kainate 3 | 0.38095 | Riluzole
| 0.34712 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 349 | N | N | N | Verapamil hydrochloride
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.97059 | Verapamil
| 0.20857 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 350 | Y | Y | N | Glyburide
| ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 | 0.29412 | Verapamil
| 0.68192 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 351 | N | N | N | Nicardipine hydrochloride
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.67568 | Nitrendipine
| 0.010062 | KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 |
| 352 | N | N | N | Quinidine sulfate
| KCNK4: potassium channel, subfamily K, member 4 | 0.20548 | Verapamil
| 0.38351 | KCNK2: potassium channel, subfamily K, member 2 |
| 353 | N | N | N | Quinidine sulfate
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.20548 | Verapamil
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 354 | N | N | N | Verapamil
| CHRND: cholinergic receptor, nicotinic, delta | 0.29268 | Metoclopramide
| 0.029958 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 355 | N | N | N | Diazoxide
| GRIK2: glutamate receptor, ionotropic, kainate 2 | 0.034483 | Kainic acid hydrate
| 0.36035 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 356 | N | N | N | Levetiracetam
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.30769 | Dyclonine hydrochloride
| 0.76982 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 357 | N | N | N | Bethanidine sulfate
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.30952 | Trimipramine
| 0.49354 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 358 | N | N | N | Quinine sulfate
| KCNK2: potassium channel, subfamily K, member 2 | 1 | Quinidine sulfate
| 0.034129 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 359 | N | N | N | Verapamil hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.97059 | Verapamil
| 0.029136 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 360 | N | N | N | Verapamil
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.20000 | Riluzole
| 0.020345 | KCNE1L: KCNE1-like |
| 361 | N | N | N | Alprazolam
| GLRA1: glycine receptor, alpha 1 | 0.68000 | Diazepam
| 0.32784 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 362 | N | N | N | Metocurine iodide
| CHRNA4: cholinergic receptor, nicotinic, alpha 4 | 0.67619 | Tubocurarine chloride
| 0.52847 | CHRNA2 |
| 363 | N | N | N | Dofetilide
| KCNK6: potassium channel, subfamily K, member 6 | 0.41270 | Ibutilide fumarate
| 0.19314 | KCNK2: potassium channel, subfamily K, member 2 |
| 364 | N | N | Y | Hexamethonium bromide
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.35000 | Carbachol
| 0.44784 | CHRNA2 |
| 365 | N | N | N | Moricizine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.52632 | Loratadine
 | 0.016875 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit |
| 366 | N | N | N | Metocurine iodide
| CHRNA3: cholinergic receptor, nicotinic, alpha 3 | 0.67619 | Tubocurarine chloride
| 0.52424 | CHRNA2 |
| 367 | N | N | N | Flurazepam
| GLRB | 0.62069 | Diazepam
| 0.29609 | GABRB1 |
| 368 | N | N | N | Levetiracetam
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.30769 | Dyclonine hydrochloride
| 0.75242 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 369 | N | N | N | Verapamil
| P2RX2: purinergic receptor P2X, ligand-gated ion channel, 2 | 0.17500 | Caffeine
| 0.042682 | KCNK4: potassium channel, subfamily K, member 4 |
| 370 | N | N | N | Diazoxide
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.27027 | Glyburide
| 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 371 | N | N | N | Flecainide acetate
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.27027 | Riluzole
| 0.015652 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 372 | N | N | Y | Topiramate
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.20000 | Mexiletine hydrochloride
| 0.76982 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 373 | N | N | N | Alprazolam
| GLRB | 0.68000 | Diazepam
| 0.29609 | GABRB1 |
| 374 | N | N | N | Verapamil
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.29268 | Metoclopramide
| 0.035142 | KCNK4: potassium channel, subfamily K, member 4 |
| 375 | N | N | N | Indapamide
 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.42857 | Benzthiazide
| 0.022575 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 376 | N | N | N | Amlexanox
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.38235 | Caffeine and sodium benzoate
 | 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 377 | N | N | N | Quinine sulfate
| KCNH5: potassium voltage-gated channel, subfamily H (eag-related), member 5 | 1 | Quinidine sulfate
| 0.015687 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 378 | N | N | N | Bupivacaine hydrochloride
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 0.34146 | Flecainide acetate
| 0.51877 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 379 | N | N | N | Penfluridol
| CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | 0.64729 | Pimozide
| 0.11362 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 380 | N | N | Y | Disopyramide
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.45714 | Propafenone hydrochloride
| 0.86296 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 381 | N | N | N | Tolbutamide
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.41667 | Glyburide
| 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 382 | N | N | Y | Topiramate
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.20000 | Mexiletine hydrochloride
| 0.75242 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 383 | N | N | N | Isoflurane
| GLRA3 | 0.032258 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 384 | N | N | Y | Oxcarbazepine
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.76191 | Carbamazepine
| 0.60341 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 385 | N | N | N | Pentobarbital
| GLRA1: glycine receptor, alpha 1 | 0.16000 | Propofol
| 0.32784 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 386 | N | N | N | Levetiracetam
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.26087 | Ketamine hydrochloride
| 0.0099594 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 387 | N | N | N | Nortriptyline hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.48276 | Fluoxetine
| 0.55275 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 388 | N | N | N | Isradipine
| CACNB3: calcium channel, voltage-dependent, beta 3 subunit | 0.66667 | Nisoldipine
| 0.48563 | CACNB2: calcium channel, voltage-dependent, beta 2 subunit |
| 389 | Y | N | Y | Ondansetron
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.88000 | Ondansetron hydrochloride hydrate
| 0.16111 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 390 | N | N | N | Amitriptyline hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.50000 | Thioridazine hydrochloride
| 0.030674 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 391 | N | N | N | Diazoxide
| CLCN2: chloride channel 2 | 0.051282 | Lubiprostone
| 0.022598 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 392 | N | N | N | Verapamil
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0 | Proline
| 0.033290 | KCNK17: potassium channel, subfamily K, member 17 |
| 393 | N | N | N | Quinidine gluconate
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.31579 | Diltiazem malate
| 0.59825 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 394 | N | N | N | Ibutilide fumarate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.29167 | Verapamil
| 0.19447 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
| 395 | N | N | N | Guanadrel sulfate
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.17021 | Dextromethorphan
| 0.49354 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 396 | N | N | N | Anastrozole
 | CHRNE: cholinergic receptor, nicotinic, epsilon | 0.23529 | Metoclopramide
| 0.31850 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 397 | N | N | N | Ethosuximide
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.15790 | Gabapentin
| 0.12631 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 398 | N | N | N | Ibutilide fumarate
| CACNB4: calcium channel, voltage-dependent, beta 4 subunit | 0.29167 | Verapamil
| 0.56963 | CACNB1: calcium channel, voltage-dependent, beta 1 subunit |
| 399 | N | N | N | Amlexanox
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.37500 | Repaglinide
 | 0.013742 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 400 | N | N | N | Desipramine hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.48276 | Fluoxetine
| 0.55275 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 401 | N | N | N | Verapamil
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0 | Proline
| 0.031499 | KCNK16: potassium channel, subfamily K, member 16 |
| 402 | N | Y | N | Quinidine sulfate
| KCNK1: potassium channel, subfamily K, member 1 | 0.20548 | Verapamil
| 0.38862 | KCNK6: potassium channel, subfamily K, member 6 |
| 403 | N | N | N | Gallopamil hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.86486 | Verapamil
| 0.0095753 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 404 | N | N | N | Isradipine
| PKD1: polycystic kidney disease 1 (autosomal dominant) | 0.66667 | Nisoldipine
| 0.0092008 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 405 | N | N | N | Enflurane
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.20000 | Flecainide acetate
| 0.79208 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 406 | N | N | N | Phenacemide
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.40000 | Tocainide hydrochloride
| 0.83065 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 407 | N | N | N | Quinine sulfate
| KCNK10: potassium channel, subfamily K, member 10 | 1 | Quinidine sulfate
| 0.029311 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 408 | N | N | N | Riluzole
| ACCN2: amiloride-sensitive cation channel 2, neuronal | 0.26923 | Amiloride hydrochloride
| 0.47336 | ACCN3: amiloride-sensitive cation channel 3 |
| 409 | N | N | N | Quinidine gluconate
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.19231 | Disopyramide
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 410 | N | N | N | Encainide hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.47059 | Bupivacaine hydrochloride
| 0.016875 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit |
| 411 | N | N | N | Halothane
| GLRA3 | 0.035714 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 412 | N | N | N | Riluzole
| ACCN1: amiloride-sensitive cation channel 1, neuronal | 0.26923 | Amiloride hydrochloride
| 0.48895 | ACCN3: amiloride-sensitive cation channel 3 |
| 413 | N | N | N | Trimipramine
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.51852 | Oxcarbazepine
| 0.013973 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 414 | N | N | N | Riluzole
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.23077 | Ketamine hydrochloride
| 0.44349 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 415 | N | N | N | Quinine sulfate
| KCNK6: potassium channel, subfamily K, member 6 | 1 | Quinidine sulfate
| 0.041460 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 416 | N | N | N | Prilocaine
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.94118 | Prilocaine hydrochloride
| 0.58238 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 417 | N | N | N | Verapamil
| GLRA3 | 0.14583 | Tropisetron hydrochloride
| 0.029733 | KCNE1L: KCNE1-like |
| 418 | N | N | N | Flurazepam
| GLRA1: glycine receptor, alpha 1 | 0.62069 | Diazepam
| 0.32784 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 419 | N | N | N | Verapamil hydrochloride
| KCNC4: potassium voltage-gated channel, Shaw-related subfamily, member 4 | 0.97059 | Verapamil
| 0.63607 | KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 |
| 420 | N | N | N | Felodipine
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.75862 | Nitrendipine
| 0.51802 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 421 | N | N | N | Penfluridol
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.48936 | Astemizole
 | 0.013728 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 422 | Y | N | Y | Prilocaine
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.94118 | Prilocaine hydrochloride
| 0.60301 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 423 | N | N | N | Phencyclidine hydrochloride
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.40909 | Nicotine
| 0.44784 | CHRNA2 |
| 424 | N | N | N | Metocurine iodide
| CHRNA6: cholinergic receptor, nicotinic, alpha 6 | 0.67619 | Tubocurarine chloride
| 0.49191 | CHRNA2 |
| 425 | N | N | N | Quinine sulfate
| KCNK16: potassium channel, subfamily K, member 16 | 1 | Quinidine sulfate
| 0.033222 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 426 | N | N | N | Mitiglinide calcium hydrate
 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.30909 | Nateglinide
| 0.39373 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 427 | Y | N | N | Tubocurarine chloride
| GABRG3 | 0.23975 | Midazolam
| 0.40101 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 428 | N | N | N | Midazolam
| GLRA1: glycine receptor, alpha 1 | 0.59259 | Diazepam
| 0.32784 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 429 | N | N | N | Ketamine hydrochloride
| GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 | 0.37500 | Flurazepam
| 0.43368 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 430 | Y | Y | N | Pimozide
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.65854 | Astemizole
| 0.017111 | CACNB2: calcium channel, voltage-dependent, beta 2 subunit |
| 431 | N | N | N | Phenacemide
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.40000 | Tocainide hydrochloride
| 0.76982 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 432 | N | N | N | Lubiprostone
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.25926 | Penicillin G procaine
 | 0.013899 | CLCN2: chloride channel 2 |
| 433 | N | N | N | Verapamil
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.12245 | Cocaine
| 0.033720 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 434 | N | N | N | Quinine sulfate
| KCNH1: potassium voltage-gated channel, subfamily H (eag-related), member 1 | 1 | Quinidine sulfate
| 0.016688 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 435 | N | N | N | Hexamethonium bromide
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.35000 | Carbachol
| 0.31221 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 436 | N | N | N | Pentobarbital
| GLRA2: glycine receptor, alpha 2 | 0.16000 | Propofol
| 0.32569 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 437 | N | N | N | Phenacemide
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.40000 | Tocainide hydrochloride
| 0.75242 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 438 | N | Y | N | Nicotine bitartrate
 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.35294 | Nicotine
| 0.44784 | CHRNA2 |
| 439 | N | N | N | Quinidine sulfate
| KCNA6: potassium voltage-gated channel, shaker-related subfamily, member 6 | 0.20548 | Verapamil
| 0.57211 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 440 | N | N | N | Diazoxide
| MCOLN1: mucolipin 1 | 0.18518 | Amiloride hydrochloride
| 0.032255 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 441 | N | N | N | Ethotoin
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.36000 | Phenytoin
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 442 | N | N | N | Felodipine
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.75862 | Nitrendipine
| 0.13350 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 443 | N | N | N | Amlexanox
| ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 | 0.27907 | Verapamil
| 0.68192 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 444 | N | N | N | Procaine hydrochloride
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.57895 | Benzocaine
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 445 | N | N | N | Diazoxide
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.18518 | Amiloride hydrochloride
| 0.027859 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
| 446 | N | N | N | Proline
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.19048 | Methylphenidate
| 0.41013 | SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 |
| 447 | N | N | N | Felodipine
| CACNA1B: calcium channel, voltage-dependent, N type, alpha 1B subunit | 0.75862 | Nitrendipine
| 0.58498 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 448 | Y | N | N | Haloperidol
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.52632 | Cisapride
 | 0.014090 | GRIN2C: glutamate receptor, ionotropic, N-methyl D-aspartate 2C |
| 449 | N | N | N | Quinidine sulfate
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.16667 | Cocaine
| 0.46734 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 450 | N | N | N | Glipizide
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.77778 | Glyburide
| 0.014445 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 451 | N | N | N | Propafenone hydrochloride
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.34091 | Verapamil
| 0.55968 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 452 | N | N | N | Methoxyflurane
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.17647 | Flecainide acetate
| 0.79208 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 453 | Y | N | N | Dextromethorphan
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.42308 | Ketamine hydrochloride
| 0.44349 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 454 | N | N | N | Amiodarone hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.58333 | Dibucaine
| 0.025844 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 455 | N | N | N | Quinidine gluconate
| KCNA6: potassium voltage-gated channel, shaker-related subfamily, member 6 | 0.18644 | Verapamil
| 0.57211 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 456 | N | N | N | Dopamine hydrochloride
| GLRA3 | 0.21429 | Tropisetron hydrochloride
| 0.095753 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 457 | N | Y | N | Amlodipine maleate
| CACNA1B: calcium channel, voltage-dependent, N type, alpha 1B subunit | 0.48837 | Nisoldipine
| 0.58498 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 458 | N | N | N | Levetiracetam
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.30769 | Dyclonine hydrochloride
| 0.60301 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 459 | N | N | N | Levobupivacaine hydrochloride
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.95652 | Bupivacaine hydrochloride
| 0.027135 | KCNK5: potassium channel, subfamily K, member 5 |
| 460 | N | Y | N | Butabarbital
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 0.82353 | Pentobarbital
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 461 | N | N | N | Fluphenazine hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.44737 | Fluoxetine hydrochloride
| 0.55275 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 462 | N | N | N | Verapamil
| P2RX7: purinergic receptor P2X, ligand-gated ion channel, 7 | 0.17500 | Caffeine
| 0.027427 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 463 | N | N | N | Nicotine bitartrate
| KCND2: potassium voltage-gated channel, Shal-related subfamily, member 2 | 0.11628 | Diazoxide
| 0.74853 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 464 | N | N | N | Guanethidine sulfate
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.17778 | Dextromethorphan
| 0.49354 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 465 | N | N | N | Sevoflurane
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.25714 | Flecainide acetate
| 0.79208 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 466 | N | N | N | Ondansetron hydrochloride hydrate
| GLRA3 | 0.34286 | Tropisetron hydrochloride
| 0.095753 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 467 | N | N | N | Quinidine sulfate
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.31884 | Ketoconazole
| 0.54502 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 468 | N | N | N | Trifluoperazine maleate
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.45833 | Thioridazine hydrochloride
| 0.030674 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 469 | N | N | N | Thioridazine
 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.54054 | Fluphenazine hydrochloride
| 0.024221 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 470 | N | N | N | Benzocaine
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.31034 | Nitrendipine
| 0.12677 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 471 | N | N | N | Diltiazem hydrochloride
| KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 | 0.39130 | Verapamil hydrochloride
| 0.63973 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 472 | N | N | N | Metocurine iodide
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.67619 | Tubocurarine chloride
| 0.077681 | CHRNA2 |
| 473 | N | N | N | Ibutilide fumarate
| KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 | 0.29167 | Verapamil
| 0.66902 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 474 | N | N | N | Benzocaine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.31034 | Nitrendipine
| 0.12915 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 475 | N | N | N | Amlodipine maleate
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.48837 | Nisoldipine
| 0.51802 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 476 | N | N | N | Granisetron hydrochloride
| GLRA2: glycine receptor, alpha 2 | 0.53333 | Tropisetron hydrochloride
| 0.10113 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 477 | N | N | N | Proline
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.16667 | Dextromethorphan
| 0.38489 | SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 |
| 478 | N | N | N | Diazoxide
| GRIK1: glutamate receptor, ionotropic, kainate 1 | 0.38095 | Riluzole
| 0.34713 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
| 479 | N | N | N | Trimethadione
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.28571 | Hexobarbital
 | 0.0087226 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 480 | Y | N | N | Cyclothiazide
| GRIA4: glutamate receptor, ionotrophic, AMPA 4 | 0.26667 | Diazoxide
| 0.73920 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 481 | N | N | N | Quinidine gluconate
| KCNK17: potassium channel, subfamily K, member 17 | 0.18644 | Verapamil
| 0.34803 | KCNK16: potassium channel, subfamily K, member 16 |
| 482 | N | N | N | Tropisetron hydrochloride
| GABRR2 | 0.35484 | Diazepam
| 0.29902 | GLRA2: glycine receptor, alpha 2 |
| 483 | Y | N | Y | Carbamazepine
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.40000 | Moricizine hydrochloride
| 0.86296 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 484 | N | N | Y | Mecamylamine hydrochloride
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.20000 | Carbachol
| 0.31221 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 485 | N | N | N | Terfenadine
 | KCNH7: potassium voltage-gated channel, subfamily H (eag-related), member 7 | 0.27114 | Verapamil
| 0.52729 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 486 | N | N | N | Dantrolene
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.41935 | Clobazam
 | 0.0064074 | RYR1: ryanodine receptor 1 (skeletal) |
| 487 | N | N | N | Cetiedil citrate
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.20690 | Glyburide
| 0.010929 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 488 | N | N | N | Flecainide acetate
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.27027 | Riluzole
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 489 | N | N | N | Verapamil hydrochloride
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.97059 | Verapamil
| 0.14611 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 490 | N | N | N | Disopyramide
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.34884 | Verapamil
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 491 | Y | N | Y | Tocainide
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.93333 | Tocainide hydrochloride
| 0.58238 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 492 | N | N | N | Ketoconazole
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.40816 | Glyburide
| 0.011075 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 493 | N | N | N | Levobupivacaine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.95652 | Bupivacaine hydrochloride
| 0.021715 | KCNK5: potassium channel, subfamily K, member 5 |
| 494 | Y | N | N | Cyclothiazide
| GRIA3: glutamate receptor, ionotrophic, AMPA 3 | 0.26667 | Diazoxide
| 0.73123 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 495 | N | N | N | Diazoxide
| SCN4B | 0.40000 | Zonisamide
| 0.044678 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 496 | N | N | N | Metocurine iodide
| CHRNA5: cholinergic receptor, nicotinic, alpha 5 | 0.67619 | Tubocurarine chloride
| 0.44323 | CHRNA2 |
| 497 | N | N | N | Verapamil hydrochloride
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.97059 | Verapamil
| 0.12559 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 498 | N | N | N | Quinidine gluconate
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.20408 | Cocaine
| 0.46734 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 499 | N | N | N | Thioridazine hydrochloride
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.64706 | Trifluoperazine hydrochloride
| 0.030674 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 500 | N | N | N | Halazepam
 | GLRA1: glycine receptor, alpha 1 | 0.76000 | Diazepam
| 0.31459 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 501 | N | N | N | Cetiedil citrate
| CHRNA2 | 0.33962 | Nicotine bitartrate
| 0.019239 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 502 | N | N | N | Quinidine sulfate
| KCNK17: potassium channel, subfamily K, member 17 | 0.20548 | Verapamil
| 0.34803 | KCNK16: potassium channel, subfamily K, member 16 |
| 503 | N | N | N | Riluzole
| GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 | 0.23077 | Ketamine hydrochloride
| 0.15710 | GRIK1: glutamate receptor, ionotropic, kainate 1 |
| 504 | N | N | N | Ibutilide fumarate
| CACNB3: calcium channel, voltage-dependent, beta 3 subunit | 0.29167 | Verapamil
| 0.49490 | CACNB1: calcium channel, voltage-dependent, beta 1 subunit |
| 505 | N | N | N | Procaine hydrochloride
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.33333 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 506 | N | N | N | Verapamil
| P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 | 0.17500 | Caffeine
| 0.045889 | KCNE1L: KCNE1-like |
| 507 | N | N | N | Chlorothiazide
 | GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.51852 | Cyclothiazide
| 0.010212 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 508 | N | N | N | Tolazamide
| KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 | 0.25000 | Diazoxide
| 0.66902 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 509 | N | N | N | Quinine hydrochloride hydrate
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.29546 | Diltiazem hydrochloride
| 0.66887 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 510 | N | N | Y | Pentobarbital calcium
 | GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 | 0.40000 | Pentobarbital
| 0.43368 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 511 | N | N | N | Felodipine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.75862 | Nitrendipine
| 0.10257 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 512 | N | N | N | Felbamate
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.19444 | Haloperidol
| 0.44349 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 513 | N | N | N | Flecainide acetate
| KCNC4: potassium voltage-gated channel, Shaw-related subfamily, member 4 | 0.20370 | Verapamil
| 0.64803 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 514 | Y | N | Y | Prilocaine
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.94118 | Prilocaine hydrochloride
| 0.60341 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 515 | N | Y | N | Verapamil hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.97059 | Verapamil
| 0.11951 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 516 | N | N | N | Disopyramide
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.34884 | Verapamil
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 517 | N | N | N | Mefloquine hydrochloride
 | GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.31250 | Riluzole
| 0.011082 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 518 | N | N | N | Glyburide
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.40816 | Ketoconazole
| 0.017942 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 519 | N | N | N | Loratadine
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.32558 | Diltiazem hydrochloride
| 0.55968 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 520 | N | N | N | Diazepam
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.30769 | Diazoxide
| 0.018959 | GLRA1: glycine receptor, alpha 1 |
| 521 | N | N | N | Gallopamil hydrochloride
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.86486 | Verapamil
| 0.012500 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 522 | N | N | Y | Tubocurarine chloride
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.16364 | Nicotine
| 0.31221 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 523 | N | N | N | Amlodipine besylate
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.57447 | Nicardipine hydrochloride
| 0.020088 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 524 | Y | Y | Y | Repaglinide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.43478 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 525 | N | N | N | Ibutilide fumarate
| KCNK16: potassium channel, subfamily K, member 16 | 0.29167 | Verapamil
| 0.24996 | KCNK6: potassium channel, subfamily K, member 6 |
| 526 | N | N | N | Bupivacaine hydrochloride
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.34146 | Flecainide acetate
| 0.55968 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 527 | N | N | N | Zonisamide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.40000 | Diazoxide
| 0.016547 | SCN1B: sodium channel, voltage-gated, type I, beta |
| 528 | N | N | N | Verapamil
| P2RX3: purinergic receptor P2X, ligand-gated ion channel, 3 | 0.17500 | Caffeine
| 0.030341 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 529 | N | N | Y | Tolazamide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.56000 | Tolbutamide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 530 | N | N | N | Mepivacaine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.75000 | Bupivacaine hydrochloride
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 531 | N | N | N | Exemestane
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.18750 | Pentobarbital
| 0.31850 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 532 | N | N | N | Encainide hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.65625 | Thioridazine hydrochloride
| 0.016835 | SCN2A: sodium channel, voltage-gated, type II, alpha subunit |
| 533 | N | N | N | Amlodipine maleate
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.48837 | Nisoldipine
| 0.018083 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 534 | N | N | N | Verapamil hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.97059 | Verapamil
| 0.032967 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 535 | N | N | N | Halazepam
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.39286 | Riluzole
| 0.011445 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 536 | N | N | Y | Moricizine
 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.96774 | Moricizine hydrochloride
| 0.58238 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 537 | N | N | N | Amlodipine besylate
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.48837 | Nitrendipine
| 0.018083 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 538 | N | N | N | Metoclopramide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.56000 | Chloroprocaine hydrochloride
 | 0.013456 | CHRNA1: cholinergic receptor, nicotinic, alpha 1 (muscle) |
| 539 | N | N | N | Verapamil
| P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 | 0.17500 | Caffeine
| 0.029220 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 540 | N | N | N | Halofantrine hydrochloride
 | KCNH7: potassium voltage-gated channel, subfamily H (eag-related), member 7 | 0.36735 | Verapamil
| 0.52729 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 541 | N | Y | N | Zonisamide
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.16129 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 542 | Y | Y | N | Sertraline
| SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.53846 | Mazindol
| 0.48799 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 543 | N | N | N | Chloroprocaine hydrochloride
| RYR2: ryanodine receptor 2 (cardiac) | 0.85000 | Procaine hydrochloride
| 0.0081086 | KCNK5: potassium channel, subfamily K, member 5 |
| 544 | N | N | N | Diazoxide
| CHRND: cholinergic receptor, nicotinic, delta | 0.25926 | Metoclopramide
| 0.029958 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 545 | N | N | N | Benoxinate hydrochloride
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.80000 | Proparacaine hydrochloride
| 0.51890 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 546 | N | N | N | Dequalinium chloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.34783 | Thioridazine hydrochloride
| 0.032967 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 547 | N | N | N | Verapamil
| GABRR2 | 0.30233 | Zaleplon
| 0.030883 | KCNE1L: KCNE1-like |
| 548 | N | N | N | Flecainide acetate
| KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 | 0.22222 | Verapamil hydrochloride
| 0.63973 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 549 | N | N | N | Isoflurane
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.23529 | Flecainide acetate
| 0.79208 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 550 | N | N | N | Fluoxetine hydrochloride
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.34091 | Ketoconazole
| 0.34860 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 551 | N | N | Y | Disopyramide
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.45714 | Propafenone hydrochloride
| 0.75410 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 552 | N | N | N | Chloroprocaine hydrochloride
| RYR3 | 0.85000 | Procaine hydrochloride
| 0.0065468 | KCNK5: potassium channel, subfamily K, member 5 |
| 553 | N | N | N | Metoclopramide
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.72727 | Procainamide hydrochloride
| 0.015351 | CHRNA4: cholinergic receptor, nicotinic, alpha 4 |
| 554 | N | N | N | Levetiracetam
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.30769 | Dyclonine hydrochloride
| 0.83065 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 555 | N | N | N | Mefloquine hydrochloride
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.47500 | Flecainide acetate
| 0.081115 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 556 | N | N | N | Verapamil hydrochloride
| KCNJ5: potassium inwardly-rectifying channel, subfamily J, member 5 | 0.97059 | Verapamil
| 0.70666 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 557 | N | N | N | Methoxyflurane
| GLRA3 | 0.071429 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 558 | N | N | N | Alprazolam
| GLRA2: glycine receptor, alpha 2 | 0.68000 | Diazepam
| 0.32569 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 559 | N | N | N | Verapamil hydrochloride
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.97059 | Verapamil
| 0.035140 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 560 | N | N | N | Pramoxine hydrochloride
 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.38461 | Flecainide acetate
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 561 | N | Y | Y | Nateglinide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.36585 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 562 | N | N | N | Fluoxetine
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.34884 | Ketoconazole
| 0.34860 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 563 | N | N | N | Verapamil
| P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 | 0.17500 | Caffeine
| 0.045455 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 564 | N | N | N | Exemestane
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.34483 | Hexobarbital
| 0.090264 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 565 | N | N | N | Riluzole
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38095 | Diazoxide
| 0.025836 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit |
| 566 | N | N | N | Dofetilide
| KCNK16: potassium channel, subfamily K, member 16 | 0.40909 | Verapamil
| 0.27152 | KCNK2: potassium channel, subfamily K, member 2 |
| 567 | N | N | N | Terfenadine
| KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 | 0.27114 | Verapamil
| 0.50037 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 568 | N | N | Y | Topiramate
| GRIK5: glutamate receptor, ionotropic, kainate 5 | 0.15152 | Kainic acid hydrate
| 0.37570 | GRIK1: glutamate receptor, ionotropic, kainate 1 |
| 569 | N | N | N | Verapamil hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.97059 | Verapamil
| 0.032538 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 570 | N | Y | N | Magnesium sulfate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.027027 | Nifedipine
| 0.015801 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 571 | N | N | N | Bupivacaine hydrochloride
| KCND2: potassium voltage-gated channel, Shal-related subfamily, member 2 | 0.19355 | Diazoxide
| 0.74853 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 572 | N | N | N | Ketamine hydrochloride
| GABRG3 | 0.37500 | Flurazepam
| 0.40101 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 573 | N | N | N | Tolbutamide
| ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 | 0.18605 | Verapamil
| 0.68192 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 574 | N | N | N | Tropisetron hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.39286 | Ketamine hydrochloride
| 0.32323 | GLRA3 |
| 575 | N | N | N | Profenamine hydrochloride
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.37143 | Dizocilpine maleate
| 0.44349 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 576 | N | N | N | Desflurane
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 1 | Isoflurane
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 577 | N | N | N | Cyproheptadine hydrochloride
| CHRNA2 | 0.39317 | Tubocurarine chloride
| 0.018097 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 578 | N | N | N | Ketoconazole
| KCNH7: potassium voltage-gated channel, subfamily H (eag-related), member 7 | 0.25455 | Verapamil
| 0.52729 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 579 | N | N | N | Enflurane
| GLRA3 | 0.032258 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 580 | N | N | N | Diltiazem malate
| KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 | 0.33962 | Verapamil
| 0.63973 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 581 | N | N | N | Zonisamide
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.22222 | Phenytoin
| 0.12631 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 582 | N | N | N | Dofetilide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.41026 | Benzthiazide
| 0.022874 | KCNK2: potassium channel, subfamily K, member 2 |
| 583 | N | N | N | Ibutilide fumarate
| KCNK2: potassium channel, subfamily K, member 2 | 0.41270 | Dofetilide
| 0.20401 | KCNK1: potassium channel, subfamily K, member 1 |
| 584 | N | N | N | Isradipine
| CACNG7 | 0.66667 | Nisoldipine
| 0.094539 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 585 | N | Y | N | Felodipine
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.75862 | Nitrendipine
| 0.11063 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 586 | N | N | N | Chloroprocaine hydrochloride
| RYR1: ryanodine receptor 1 (skeletal) | 0.85000 | Procaine hydrochloride
| 0.0085784 | KCNK5: potassium channel, subfamily K, member 5 |
| 587 | N | N | N | Methylphenidate
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.56000 | Cocaine
| 0.012733 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
| 588 | N | N | Y | Tubocurarine chloride
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.16129 | Metoclopramide
| 0.34687 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 589 | N | N | Y | Topiramate
| GRIK4: glutamate receptor, ionotropic, kainate 4 | 0.15152 | Kainic acid hydrate
| 0.36616 | GRIK1: glutamate receptor, ionotropic, kainate 1 |
| 590 | N | N | N | Diazoxide
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.25926 | Metoclopramide
| 0.035142 | KCNK4: potassium channel, subfamily K, member 4 |
| 591 | N | N | N | Procainamide hydrochloride
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.72727 | Metoclopramide
| 0.010863 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 592 | N | N | N | Nicotine bitartrate
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.35294 | Nicotine
| 0.31221 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 593 | N | N | N | Carbamazepine
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.17647 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 594 | N | N | Y | Topiramate
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.20000 | Mexiletine hydrochloride
| 0.83065 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 595 | N | N | N | Ethchlorvynol
 | GLRA1: glycine receptor, alpha 1 | 0.21429 | Methoxyflurane
| 0.31459 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 596 | N | N | N | Magnesium sulfate
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.10345 | Glyclopyramide
| 0.025831 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 597 | N | N | N | Tocainide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.63158 | Lidocaine
 | 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 598 | N | N | Y | Disopyramide
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.45714 | Propafenone hydrochloride
| 0.72659 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 599 | N | N | N | Ropivacaine hydrochloride
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.87500 | Bupivacaine hydrochloride
| 0.027135 | KCNK5: potassium channel, subfamily K, member 5 |
| 600 | N | N | N | Letrozole
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.34884 | Ketoconazole
| 0.017956 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 601 | N | N | N | Gallopamil hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.86486 | Verapamil
| 0.0096347 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 602 | N | N | N | Cisapride
| KCNH7: potassium voltage-gated channel, subfamily H (eag-related), member 7 | 0.35417 | Verapamil
| 0.52729 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 603 | N | N | N | Tubocurarine chloride
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.30378 | Ketoconazole
| 0.34860 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 604 | N | N | N | Granisetron
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.48387 | Nateglinide
| 0.017658 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 605 | N | N | N | Aminoglutethimide
| CHRNA2 | 0.32000 | Pentobarbital
| 0.44784 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 606 | N | N | N | Diazoxide
| SCN3B: sodium channel, voltage-gated, type III, beta | 0.40000 | Zonisamide
| 0.046014 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 607 | N | N | N | Isradipine
| TRPV6: transient receptor potential cation channel, subfamily V, member 6 | 0.66667 | Nisoldipine
| 0.019119 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 608 | N | N | N | Felbamate
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.40000 | Etomidate
| 0.31643 | GLRA2: glycine receptor, alpha 2 |
| 609 | N | N | N | Gallopamil hydrochloride
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.86486 | Verapamil
| 0.023214 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 610 | N | N | N | Dequalinium chloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.40000 | Halofantrine hydrochloride
| 0.017196 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 611 | N | N | N | Profenamine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.56250 | Flurazepam
| 0.011071 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 612 | N | N | N | Furosemide
| GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 | 0.32258 | Diazepam
| 0.43368 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 613 | N | N | N | Glipizide
| KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 | 0.25000 | Diazoxide
| 0.66902 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 614 | N | N | Y | Tocainide
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.93333 | Tocainide hydrochloride
| 0.60341 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 615 | N | N | N | Cisapride
 | KCNH7: potassium voltage-gated channel, subfamily H (eag-related), member 7 | 0.34694 | Verapamil
| 0.52729 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 616 | N | N | N | Midazolam
| GLRB | 0.59259 | Diazepam
| 0.29609 | GABRB1 |
| 617 | N | N | N | Prilocaine
| KCNK5: potassium channel, subfamily K, member 5 | 0.94118 | Prilocaine hydrochloride
| 0.010777 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 618 | N | N | N | Quinine hydrochloride hydrate
| KCNB1: potassium voltage-gated channel, Shab-related subfamily, member 1 | 0.24242 | Diazoxide
| 0.58646 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 |
| 619 | Y | N | Y | Cocaine
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.33333 | Procaine hydrochloride
| 0.60301 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 620 | N | N | N | Diazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38889 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 621 | N | N | N | Butabarbital
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.82353 | Pentobarbital
| 0.072378 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 622 | N | N | N | Isradipine
| TRPA1: transient receptor potential cation channel, subfamily A, member 1 | 0.66667 | Nisoldipine
| 0.015142 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 623 | N | Y | N | Nimodipine
| CACNB4: calcium channel, voltage-dependent, beta 4 subunit | 0.75000 | Nitrendipine
| 0.54913 | CACNB2: calcium channel, voltage-dependent, beta 2 subunit |
| 624 | N | N | N | Fluoxetine
| KCNJ5: potassium inwardly-rectifying channel, subfamily J, member 5 | 0.34146 | Verapamil
| 0.70666 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 625 | Y | N | Y | Benzocaine
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.57895 | Procaine hydrochloride
| 0.86296 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 626 | N | N | N | Diazoxide
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.16129 | Cocaine
| 0.026833 | KCND2: potassium voltage-gated channel, Shal-related subfamily, member 2 |
| 627 | N | N | N | Promethazine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.56667 | Thioridazine hydrochloride
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 628 | N | N | N | Proline
| SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.19048 | Methylphenidate
| 0.40340 | SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 |
| 629 | N | Y | N | Butabarbital
| GABRA5: gamma-aminobutyric acid (GABA) A receptor, alpha 5 | 0.82353 | Pentobarbital
| 0.69495 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 630 | N | N | N | Granisetron hydrochloride
| GLRA1: glycine receptor, alpha 1 | 0.53333 | Tropisetron hydrochloride
| 0.098396 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 631 | N | N | N | Benoxinate hydrochloride
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.80000 | Proparacaine hydrochloride
| 0.54531 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 632 | N | N | N | Ropivacaine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.87500 | Bupivacaine hydrochloride
| 0.021715 | KCNK5: potassium channel, subfamily K, member 5 |
| 633 | N | N | N | Benzocaine
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.31034 | Nitrendipine
| 0.13951 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 634 | N | N | N | Desipramine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.51613 | Thioridazine hydrochloride
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 635 | N | N | N | Benoxinate hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.70833 | Procaine hydrochloride
| 0.011241 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 636 | N | N | N | Butabarbital
| CHRNA2 | 0.82353 | Pentobarbital
| 0.077681 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 637 | N | N | N | Verapamil
| P2RX4: purinergic receptor P2X, ligand-gated ion channel, 4 | 0.17500 | Caffeine
| 0.033352 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 638 | N | N | N | Phencyclidine hydrochloride
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.40909 | Nicotine
| 0.31221 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 639 | N | N | N | Magnesium sulfate
| CACNA2D2: calcium channel, voltage-dependent, alpha 2/delta subunit 2 | 0.027027 | Nifedipine
| 0.52208 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
| 640 | N | N | N | Halofantrine hydrochloride
| KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 | 0.36735 | Verapamil
| 0.50037 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 641 | N | N | N | Diazoxide
| SCN1B: sodium channel, voltage-gated, type I, beta | 0.40000 | Zonisamide
| 0.045507 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 642 | N | N | N | Benoxinate hydrochloride
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.80000 | Proparacaine hydrochloride
| 0.53503 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 643 | N | N | N | Methoxyflurane
| KCNK13: potassium channel, subfamily K, member 13 | 0.66667 | Halothane
| 0.027455 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 644 | N | N | N | Methoxyflurane
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.66667 | Halothane
| 0.031390 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 645 | N | N | N | Quinine hydrochloride hydrate
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 0.60000 | Quinidine gluconate
| 0.56382 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 646 | N | N | N | Fluphenazine maleate
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.36364 | Fluoxetine
| 0.55275 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 647 | N | N | N | Halofantrine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.012494 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 648 | N | N | N | Letrozole
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.13333 | Nicotine
| 0.31850 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 649 | N | N | N | Phentermine
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.38889 | Mexiletine hydrochloride
| 0.010278 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
| 650 | N | N | N | Dyclonine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.45161 | Bupivacaine hydrochloride
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 651 | N | N | N | Diazoxide
| P2RX2: purinergic receptor P2X, ligand-gated ion channel, 2 | 0.21739 | Caffeine
| 0.042682 | KCNK4: potassium channel, subfamily K, member 4 |
| 652 | N | N | N | Verapamil hydrochloride
| KCNJ9: potassium inwardly-rectifying channel, subfamily J, member 9 | 0.97059 | Verapamil
| 0.68294 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 653 | N | N | Y | Moricizine
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.96774 | Moricizine hydrochloride
| 0.60341 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 654 | N | N | N | Verapamil hydrochloride
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.97059 | Verapamil
| 0.024826 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 655 | N | N | N | Metocurine iodide
| CHRNA9: cholinergic receptor, nicotinic, alpha 9 | 0.67619 | Tubocurarine chloride
| 0.31065 | CHRNA2 |
| 656 | N | N | N | Nateglinide
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.44828 | Mepivacaine hydrochloride
| 0.0099976 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 657 | N | N | N | Gallopamil hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.86486 | Verapamil
| 0.0077683 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 658 | N | N | N | Kainic acid hydrate
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.043478 | Methoxyflurane
| 0.35409 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 659 | N | N | N | Dextromethorphan
| CHRNA3: cholinergic receptor, nicotinic, alpha 3 | 0.53571 | Codeine
 | 0.52424 | CHRNA2 |
| 660 | N | N | N | Methohexital
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.59091 | Pentobarbital
| 0.090264 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 661 | N | N | N | Verapamil hydrochloride
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.97059 | Verapamil
| 0.13105 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 662 | Y | N | N | Tubocurarine chloride
| GABRE | 0.23975 | Midazolam
| 0.33697 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 663 | N | N | N | Repaglinide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.37650 | Glipizide
| 0.39373 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 664 | N | N | N | Riluzole
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.26923 | Amiloride hydrochloride
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 665 | N | N | N | Metocurine iodide
| CHRNA1: cholinergic receptor, nicotinic, alpha 1 (muscle) | 0.67619 | Tubocurarine chloride
| 0.42204 | CHRNA2 |
| 666 | N | N | N | Diltiazem hydrochloride
| KCNC4: potassium voltage-gated channel, Shaw-related subfamily, member 4 | 0.36956 | Verapamil
| 0.64803 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 667 | N | N | N | Bepridil hydrochloride
 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.45714 | Trimipramine
| 0.014048 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
| 668 | N | N | N | Gliclazide
| KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 | 0.24138 | Diazoxide
| 0.66902 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 669 | N | N | N | Disopyramide
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.34884 | Verapamil
| 0.13951 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 670 | N | N | Y | Minoxidil
 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.28571 | Tolazamide
| 0.39373 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 671 | N | N | N | Ketoconazole
| KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 | 0.25455 | Verapamil
| 0.50037 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 672 | N | N | N | Flurazepam
| GLRA2: glycine receptor, alpha 2 | 0.62069 | Diazepam
| 0.32569 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 673 | N | N | N | Enoxacin hydrate
 | GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 | 0.22500 | Flurazepam
| 0.43368 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 674 | N | N | N | Gallopamil hydrochloride
| CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 | 0.86486 | Verapamil
| 0.0064963 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 675 | N | N | N | Thiamylal
 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.65000 | Pentobarbital
| 0.090264 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 676 | N | N | N | Quinine sulfate
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.20779 | Diltiazem malate
| 0.66887 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 677 | N | N | N | Anastrozole
| CHRNA2 | 0.23529 | Metoclopramide
| 0.44784 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 678 | N | N | N | Moricizine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.41176 | Carbamazepine
| 0.60410 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 679 | N | N | N | Penicillin G procaine
| GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 | 0.38776 | Flurazepam
| 0.43368 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 680 | N | N | N | Phenacemide
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.40000 | Tocainide hydrochloride
| 0.63042 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 681 | N | N | N | Flecainide acetate
| KCNC3: potassium voltage-gated channel, Shaw-related subfamily, member 3 | 0.20370 | Verapamil
| 0.57702 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 682 | N | N | N | Amlexanox
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38710 | Furosemide
| 0.010906 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 683 | N | N | N | Benzocaine
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.45000 | Felbamate
| 0.022827 | SCN4B |
| 684 | N | N | N | Ketoconazole
| KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 | 0.31884 | Quinidine sulfate
| 0.54502 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 685 | N | N | N | Phenacemide
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.38461 | Nateglinide
| 0.011295 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 686 | N | N | N | Felodipine
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.56410 | Nicardipine hydrochloride
| 0.020088 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 687 | N | Y | N | Primidone
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 0.43478 | Ketamine hydrochloride
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 688 | N | N | N | Biperiden
 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 | 0.50000 | Phencyclidine hydrochloride
| 0.52424 | CHRNA2 |
| 689 | N | N | N | Methylphenidate
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0.19048 | Proline
| 0.41013 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 690 | N | N | N | Quinine sulfate
| KCNK5: potassium channel, subfamily K, member 5 | 1 | Quinidine sulfate
| 0.028410 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 691 | N | N | N | Mefloquine hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.31707 | Bendroflumethiazide
 | 0.022575 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 692 | N | N | N | Metocurine iodide
| CHRNA10 | 0.67619 | Tubocurarine chloride
| 0.30303 | CHRNA2 |
| 693 | N | N | N | Isradipine
| CACNG2: calcium channel, voltage-dependent, gamma subunit 2 | 0.66667 | Nisoldipine
| 0.093335 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 694 | N | N | N | Ketoconazole
| KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 | 0.32000 | Diltiazem hydrochloride
| 0.53242 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 695 | N | N | N | Diazoxide
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.40000 | Zonisamide
| 0.030864 | KCNV1: potassium channel, subfamily V, member 1 |
| 696 | N | N | N | Quinidine gluconate
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.25862 | Ketoconazole
| 0.54502 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 697 | N | N | N | Mitiglinide calcium hydrate
| KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 | 0.15493 | Verapamil
| 0.66902 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 698 | N | Y | N | Magnesium sulfate
| CACNB1: calcium channel, voltage-dependent, beta 1 subunit | 0.042857 | Ibutilide fumarate
| 0.016265 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 699 | N | N | N | Glyclopyramide
| KCNJ8: potassium inwardly-rectifying channel, subfamily J, member 8 | 0.32000 | Diazoxide
| 0.66902 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 700 | N | N | N | Trichlormethiazide
 | GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.62963 | Cyclothiazide
| 0.010212 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 701 | N | N | N | Loratadine
| KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 | 0.35000 | Quinine hydrochloride hydrate
| 0.53491 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 702 | N | N | N | Pentobarbital
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.16129 | Metoclopramide
| 0.26265 | CHRNA10 |
| 703 | N | N | N | Codeine sulfate
 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.39744 | Quinine sulfate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 704 | N | N | N | Verapamil
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.36585 | Profenamine hydrochloride
| 0.023718 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 705 | N | N | N | Paroxetine
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.27778 | Cocaine
| 0.41406 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 706 | N | N | N | Ketamine hydrochloride
| GABRE | 0.37500 | Flurazepam
| 0.33697 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 707 | N | N | N | Disopyramide
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.20513 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 708 | N | N | N | Mefloquine hydrochloride
| GLRA1: glycine receptor, alpha 1 | 0.32432 | Tropisetron hydrochloride
| 0.015107 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 709 | N | N | N | Felbamate
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.18518 | Riluzole
| 0.092521 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 710 | N | Y | N | Butabarbital
| GABRA3: gamma-aminobutyric acid (GABA) A receptor, alpha 3 | 0.82353 | Pentobarbital
| 0.66731 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 711 | Y | N | Y | Dibucaine
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 0.48276 | Procainamide hydrochloride
| 0.60301 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 712 | N | N | N | Gabapentin
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.20833 | Ketamine hydrochloride
| 0.44349 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 713 | N | N | N | Azimilide dihydrochloride
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.015344 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 714 | N | N | N | Verapamil hydrochloride
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.97059 | Verapamil
| 0.39592 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 715 | N | N | N | Hydroflumethiazide
| GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.51724 | Cyclothiazide
| 0.010212 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 716 | N | N | N | Ethchlorvynol
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.21429 | Methoxyflurane
| 0.011445 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 717 | N | N | Y | Pentobarbital calcium
| GABRG3 | 0.40000 | Pentobarbital
| 0.40101 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 718 | N | N | N | Phencyclidine hydrochloride
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.40909 | Nicotine
| 0.26265 | CHRNA10 |
| 719 | N | N | N | Fluoxetine hydrochloride
| KCNJ5: potassium inwardly-rectifying channel, subfamily J, member 5 | 0.33333 | Verapamil
| 0.70666 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 720 | N | N | N | Quinine sulfate
| KCNB1: potassium voltage-gated channel, Shab-related subfamily, member 1 | 0.20548 | Verapamil
| 0.58646 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 |
| 721 | N | Y | N | Felodipine
| CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 | 0.75862 | Nitrendipine
| 0.0064963 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 722 | N | N | N | Verapamil
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.23404 | Ondansetron hydrochloride hydrate
| 0.042488 | KCNMB1: potassium large conductance calcium-activated channel, subfamily M, beta member 1 |
| 723 | Y | N | N | Paroxetine
| SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 0.46667 | Mazindol
| 0.48799 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 724 | Y | N | N | Phenytoin
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.56000 | Oxazepam
 | 0.025549 | SCN4B |
| 725 | N | N | N | Quinidine sulfate
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.20779 | Diltiazem malate
| 0.59825 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 726 | N | Y | N | Amlodipine besylate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.48837 | Nitrendipine
| 0.017211 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 727 | Y | N | Y | Carbamazepine
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.40000 | Moricizine hydrochloride
| 0.75410 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 728 | N | N | N | Cisapride
| KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 | 0.35417 | Verapamil
| 0.50037 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 729 | N | N | N | Profenamine hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.53125 | Propafenone hydrochloride
| 0.0097377 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 730 | N | N | N | Mirtazapine
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.51852 | Maprotiline
| 0.018814 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 731 | N | N | Y | Tubocurarine chloride
| CHRND: cholinergic receptor, nicotinic, delta | 0.16129 | Metoclopramide
| 0.33926 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 732 | N | N | N | Amiodarone hydrochloride
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.40425 | Verapamil hydrochloride
| 0.54502 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 733 | N | N | N | Diazoxide
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0 | Proline
| 0.033290 | KCNK17: potassium channel, subfamily K, member 17 |
| 734 | N | N | N | Diltiazem malate
| KCNC4: potassium voltage-gated channel, Shaw-related subfamily, member 4 | 0.33962 | Verapamil
| 0.64803 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 735 | Y | N | N | Cocaine
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.33333 | Procaine hydrochloride
| 0.58865 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 736 | Y | Y | Y | Desipramine hydrochloride
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.72000 | Trimipramine
| 0.017087 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 737 | N | N | N | Quinine hydrochloride hydrate
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.29546 | Diltiazem hydrochloride
| 0.66583 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 738 | N | N | N | Fluphenazine maleate
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.48837 | Thioridazine hydrochloride
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 739 | N | N | N | Maprotiline
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.53333 | Thioridazine
| 0.020826 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 740 | N | N | N | Ethosuximide
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.44444 | Pentobarbital
| 0.0094499 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 741 | N | N | N | Cisapride
| KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 | 0.34694 | Verapamil
| 0.50037 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 742 | N | N | N | Proparacaine hydrochloride
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.25714 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 743 | N | N | Y | Cocaine
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.33333 | Procaine hydrochloride
| 0.59648 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 744 | N | N | N | Metocurine iodide
| CHRNA7: cholinergic receptor, nicotinic, alpha 7 | 0.67619 | Tubocurarine chloride
| 0.34519 | CHRNA2 |
| 745 | N | N | N | Dopamine hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.35294 | Chlorzoxazone
 | 0.015696 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 746 | N | N | N | Propafenone hydrochloride
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.34091 | Verapamil
| 0.48532 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 747 | N | Y | N | Nimodipine
| CACNB3: calcium channel, voltage-dependent, beta 3 subunit | 0.75000 | Nitrendipine
| 0.48563 | CACNB2: calcium channel, voltage-dependent, beta 2 subunit |
| 748 | N | N | N | Mefloquine hydrochloride
| KCNE1: potassium voltage-gated channel, Isk-related family, member 1 | 0.24390 | Indapamide
| 0.026945 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 749 | N | N | N | Thioridazine hydrochloride
| KCNJ5: potassium inwardly-rectifying channel, subfamily J, member 5 | 0.34091 | Verapamil
| 0.70666 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 750 | N | N | N | Primidone
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.72222 | Ethotoin
| 0.0092349 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 751 | N | N | N | Diazoxide
| GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 | 0.29167 | Ketamine hydrochloride
| 0.14656 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
| 752 | N | N | N | Maprotiline
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.45714 | Moricizine
| 0.0094747 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 753 | N | N | N | Nicotine bitartrate
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.24490 | Quinine hydrochloride hydrate
| 0.18777 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 754 | N | N | N | Thioridazine
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.61765 | Trifluoperazine hydrochloride
| 0.030674 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 755 | N | N | N | Fluoxetine
| KCNJ9: potassium inwardly-rectifying channel, subfamily J, member 9 | 0.34146 | Verapamil
| 0.68294 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 756 | N | N | N | Halothane
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 0.54546 | Isoflurane
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 757 | N | Y | N | Butabarbital
| CHRNA4: cholinergic receptor, nicotinic, alpha 4 | 0.82353 | Pentobarbital
| 0.076957 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 758 | N | N | N | Sumatriptan
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.36000 | Diazoxide
| 0.015696 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 759 | N | N | N | Isradipine
| CACNG4: calcium channel, voltage-dependent, gamma subunit 4 | 0.66667 | Nisoldipine
| 0.077119 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 760 | N | N | N | Verapamil hydrochloride
| KCNC3: potassium voltage-gated channel, Shaw-related subfamily, member 3 | 0.97059 | Verapamil
| 0.47605 | KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 |
| 761 | N | N | N | Dofetilide
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.41270 | Ibutilide fumarate
| 0.011007 | KCNH5: potassium voltage-gated channel, subfamily H (eag-related), member 5 |
| 762 | N | Y | N | Galantamine hydrobromide
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.25926 | Nicotine
| 0.44784 | CHRNA2 |
| 763 | N | N | N | Terfenadine
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.60465 | Pimozide
| 0.0095753 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 764 | N | Y | N | Quinidine sulfate
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.32836 | Astemizole
| 0.22326 | KCNH1: potassium voltage-gated channel, subfamily H (eag-related), member 1 |
| 765 | N | Y | N | Amlodipine maleate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.48837 | Nisoldipine
| 0.017211 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 766 | N | N | N | Methoxyflurane
| KCNK12: potassium channel, subfamily K, member 12 | 0.66667 | Halothane
| 0.029641 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 767 | N | N | N | Quinine sulfate
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.31884 | Ketoconazole
| 0.53242 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 768 | N | N | N | Mibefradil dihydrochloride
| PKD1: polycystic kidney disease 1 (autosomal dominant) | 0.44898 | Verapamil
| 0.0049566 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 769 | N | N | N | Thioridazine
| KCNJ5: potassium inwardly-rectifying channel, subfamily J, member 5 | 0.34884 | Verapamil
| 0.70666 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 770 | N | N | N | Diazoxide
| P2RX7: purinergic receptor P2X, ligand-gated ion channel, 7 | 0.21739 | Caffeine
| 0.027427 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 771 | N | N | N | Physostigmine sulfate
 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.17544 | Anastrozole
| 0.44784 | CHRNA2 |
| 772 | N | N | N | Nortriptyline hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.48387 | Dizocilpine maleate
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 773 | N | N | N | Methylphenidate
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.56000 | Cocaine
| 0.012283 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 774 | N | N | N | Mepivacaine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.75000 | Bupivacaine hydrochloride
| 0.021715 | KCNK5: potassium channel, subfamily K, member 5 |
| 775 | N | N | N | Mibefradil dihydrochloride
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.44898 | Verapamil
| 0.13474 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 776 | N | N | N | Diazoxide
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0 | Proline
| 0.031499 | KCNK16: potassium channel, subfamily K, member 16 |
| 777 | N | N | N | Propafenone hydrochloride
| KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.34091 | Verapamil
| 0.21997 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 778 | N | N | N | Amlodipine besylate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.48837 | Nitrendipine
| 0.0092209 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 779 | N | N | N | Diazoxide
| GLRA3 | 0.24138 | Tropisetron hydrochloride
| 0.029733 | KCNE1L: KCNE1-like |
| 780 | N | N | N | Phencyclidine hydrochloride
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.31250 | Bupivacaine hydrochloride
| 0.18777 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 |
| 781 | N | N | N | Dopamine hydrochloride
| GLRA2: glycine receptor, alpha 2 | 0.26087 | Felbamate
| 0.10113 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 782 | N | N | N | Dextromethorphan
| CHRNA6: cholinergic receptor, nicotinic, alpha 6 | 0.53571 | Codeine
| 0.49191 | CHRNA2 |
| 783 | N | N | N | Mazindol
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.53846 | Diazepam
| 0.016836 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
| 784 | N | N | N | Bupivacaine hydrochloride
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.28571 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 785 | N | N | Y | Thiamylal
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 0.65000 | Pentobarbital
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 786 | N | N | N | Nicotine bitartrate
| KCND1: potassium voltage-gated channel, Shal-related subfamily, member 1 | 0.11628 | Diazoxide
| 0.62617 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 787 | Y | N | Y | Carbamazepine
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.40000 | Moricizine hydrochloride
| 0.72659 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 788 | N | N | N | Lamotrigine
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.35000 | Chlorzoxazone
| 0.011633 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 789 | N | N | N | Tetracaine hydrochloride
 | SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.31250 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 790 | N | N | N | Diazoxide
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.16129 | Cocaine
| 0.027170 | KCNF1: potassium voltage-gated channel, subfamily F, member 1 |
| 791 | N | N | N | Penfluridol
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.48333 | Trifluoperazine hydrochloride
| 0.011237 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 792 | N | N | N | Desflurane
| GLRA3 | 0.032258 | Tropisetron hydrochloride
| 0.83309 | GLRA1: glycine receptor, alpha 1 |
| 793 | N | N | N | Biperiden
| CHRNA6: cholinergic receptor, nicotinic, alpha 6 | 0.50000 | Phencyclidine hydrochloride
| 0.49191 | CHRNA2 |
| 794 | N | N | N | Paroxetine
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.43590 | Cisapride
| 0.013109 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 795 | N | N | N | Butabarbital
| CHRNA10 | 0.82353 | Pentobarbital
| 0.086146 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 796 | N | N | N | Astemizole
| KCNH7: potassium voltage-gated channel, subfamily H (eag-related), member 7 | 0.28846 | Verapamil
| 0.52729 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 797 | N | N | N | Methylphenidate
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0.19048 | Proline
| 0.38254 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 798 | N | N | N | Zaleplon
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.37143 | Disopyramide
| 0.013396 | GABRE |
| 799 | N | N | N | Verapamil hydrochloride
| CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 | 0.97059 | Verapamil
| 0.014097 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 800 | N | N | N | Isradipine
| ITPR1: inositol 1,4,5-trisphosphate receptor, type 1 | 0.66667 | Nisoldipine
| 0.0095944 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 801 | N | N | N | Butabarbital
| CHRNA9: cholinergic receptor, nicotinic, alpha 9 | 0.82353 | Pentobarbital
| 0.086245 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 802 | N | N | N | Physostigmine sulfate
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36986 | Quinine sulfate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 803 | N | N | N | Bupivacaine hydrochloride
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.29730 | Disopyramide
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 804 | N | N | N | Lamotrigine
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.40909 | Riluzole
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 805 | N | N | N | Phencyclidine hydrochloride
| KCNB1: potassium voltage-gated channel, Shab-related subfamily, member 1 | 0.17857 | Diazoxide
| 0.58646 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 |
| 806 | N | N | N | Propafenone hydrochloride
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.34091 | Verapamil
| 0.55487 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 807 | N | N | N | Diazoxide
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.38095 | Riluzole
| 0.092521 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
| 808 | N | N | N | Diazoxide
| ACCN2: amiloride-sensitive cation channel 2, neuronal | 0.18518 | Amiloride hydrochloride
| 0.026659 | KCNE1L: KCNE1-like |
| 809 | N | N | N | Dextromethorphan
| CHRNA4: cholinergic receptor, nicotinic, alpha 4 | 0.53571 | Codeine
| 0.52847 | CHRNA2 |
| 810 | N | N | N | Cocaine
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.36000 | Benzocaine
| 0.38926 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 811 | N | N | N | Tolbutamide
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.50000 | Procainamide hydrochloride
| 0.0099976 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 812 | N | N | N | Nicardipine hydrochloride
| KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 | 0.40425 | Diltiazem hydrochloride
| 0.54817 | KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 |
| 813 | N | N | N | Butabarbital
| CHRNA6: cholinergic receptor, nicotinic, alpha 6 | 0.82353 | Pentobarbital
| 0.087197 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 814 | N | N | N | Diltiazem hydrochloride
| KCNC3: potassium voltage-gated channel, Shaw-related subfamily, member 3 | 0.36956 | Verapamil
| 0.57702 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 815 | N | N | N | Diazoxide
| ACCN1: amiloride-sensitive cation channel 1, neuronal | 0.18518 | Amiloride hydrochloride
| 0.027845 | KCNE4: potassium voltage-gated channel, Isk-related family, member 4 |
| 816 | N | N | Y | Bepridil hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.45454 | Terfenadine
| 0.017204 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
| 817 | N | N | N | Dibucaine
| KCNK5: potassium channel, subfamily K, member 5 | 0.44828 | Lidocaine
| 0.011241 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 818 | N | N | N | Procainamide hydrochloride
| CHRNE: cholinergic receptor, nicotinic, epsilon | 0.72727 | Metoclopramide
| 0.011727 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 819 | N | N | N | Isradipine
| ITPR3: inositol 1,4,5-trisphosphate receptor, type 3 | 0.66667 | Nisoldipine
| 0.0092991 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 820 | N | N | N | Sertraline
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.48276 | Midazolam
| 0.014964 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 821 | N | N | N | Flecainide acetate
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.20000 | Cocaine
| 0.46734 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 822 | N | N | N | Mefloquine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.30769 | Halazepam
| 0.015344 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 823 | N | N | N | Quinine hydrochloride hydrate
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.60000 | Quinidine gluconate
| 0.54817 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 824 | N | N | N | Amiodarone hydrochloride
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.58333 | Dibucaine
| 0.023243 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 825 | N | N | N | Fluphenazine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.56757 | Thioridazine hydrochloride
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 826 | N | N | N | Codeine
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.35294 | Bupivacaine hydrochloride
| 0.020018 | CHRNA10 |
| 827 | N | N | N | Diltiazem hydrochloride
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36956 | Verapamil
| 0.22001 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 828 | N | N | N | Verapamil hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.97059 | Verapamil
| 0.034158 | KCNC2: potassium voltage-gated channel, Shaw-related subfamily, member 2 |
| 829 | N | N | N | Nicardipine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.40425 | Diltiazem hydrochloride
| 0.48532 | KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 |
| 830 | N | N | N | Penicillin G procaine
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.47676 | Diltiazem malate
| 0.011266 | GABRA5: gamma-aminobutyric acid (GABA) A receptor, alpha 5 |
| 831 | N | N | N | Furosemide
| GABRG3 | 0.32258 | Diazepam
| 0.40101 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 832 | N | N | N | Metocurine iodide
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.67619 | Tubocurarine chloride
| 0.016970 | CHRNA2 |
| 833 | N | N | N | Gallopamil hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.86486 | Verapamil
| 0.019162 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 834 | N | N | N | Diazoxide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.40000 | Zonisamide
| 0.025826 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
| 835 | N | N | N | Verapamil hydrochloride
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.97059 | Verapamil
| 0.047460 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 836 | N | N | N | Bupivacaine hydrochloride
| KCNA4: potassium voltage-gated channel, shaker-related subfamily, member 4 | 0.25532 | Nicardipine hydrochloride
| 0.48532 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 837 | N | N | N | Prilocaine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.53846 | Bupivacaine hydrochloride
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 838 | N | N | N | Ibutilide fumarate
| KCNK10: potassium channel, subfamily K, member 10 | 0.29167 | Verapamil
| 0.18687 | KCNK1: potassium channel, subfamily K, member 1 |
| 839 | N | N | N | Zonisamide
| PKD1: polycystic kidney disease 1 (autosomal dominant) | 0.22222 | Phenytoin
| 0.012238 | SCN1B: sodium channel, voltage-gated, type I, beta |
| 840 | N | N | N | Sertraline
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.27273 | Cocaine
| 0.41406 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 841 | N | N | N | Methoxyflurane
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.66667 | Halothane
| 0.048992 | KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) |
| 842 | N | N | N | Dizocilpine maleate
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.48387 | Nortriptyline hydrochloride
| 0.024221 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 843 | N | N | N | Amiodarone hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.42105 | Fluoxetine
| 0.021769 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 844 | N | Y | Y | Amiodarone hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.51744 | Halofantrine hydrochloride
| 0.019642 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 845 | N | N | N | Ketamine hydrochloride
| GLRA3 | 0.39286 | Tropisetron hydrochloride
| 0.32591 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 846 | N | N | N | Butabarbital
| CHRNA3: cholinergic receptor, nicotinic, alpha 3 | 0.82353 | Pentobarbital
| 0.070568 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 847 | N | N | N | Galantamine hydrobromide
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.39394 | Granisetron hydrochloride
| 0.26265 | CHRNA10 |
| 848 | N | N | N | Promethazine teoclate
| RYR1: ryanodine receptor 1 (skeletal) | 0.40476 | Caffeine and sodium benzoate
| 0.0072515 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 849 | Y | N | N | Diazoxide
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.40000 | Zonisamide
| 0.025645 | KCNF1: potassium voltage-gated channel, subfamily F, member 1 |
| 850 | N | N | N | Dyclonine hydrochloride
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.43333 | Tolazamide
| 0.021462 | KCNK5: potassium channel, subfamily K, member 5 |
| 851 | N | N | N | Kainic acid hydrate
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.28125 | Dizocilpine maleate
| 0.096106 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 852 | N | N | N | Halothane
| GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.22222 | Riluzole
| 0.69656 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
| 853 | N | N | N | Dizocilpine maleate
| GRIK2: glutamate receptor, ionotropic, kainate 2 | 0.28125 | Kainic acid hydrate
| 0.15526 | GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 |
| 854 | N | N | N | Flurazepam
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.43750 | Chloroprocaine hydrochloride
| 0.012903 | GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 |
| 855 | N | N | N | Sumatriptan
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.40741 | Tolbutamide
| 0.021953 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 856 | N | N | N | Amlodipine maleate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.48837 | Nisoldipine
| 0.0092209 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 857 | N | N | N | Desflurane
| GABRA5: gamma-aminobutyric acid (GABA) A receptor, alpha 5 | 1 | Isoflurane
| 0.69495 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 858 | N | N | Y | Flecainide acetate
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.34146 | Bupivacaine hydrochloride
| 0.24349 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 859 | N | N | N | Dizocilpine maleate
| KCNJ5: potassium inwardly-rectifying channel, subfamily J, member 5 | 0.23404 | Verapamil
| 0.70666 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 860 | N | N | N | Diltiazem hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.44444 | Fluoxetine
| 0.022791 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 861 | N | N | N | Carbamazepine
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.37037 | Phenytoin
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 862 | N | N | N | Diazoxide
| P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 | 0.21739 | Caffeine
| 0.045889 | KCNE1L: KCNE1-like |
| 863 | N | N | N | Profenamine hydrochloride
| SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 0.60714 | Trimipramine
| 0.010907 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 864 | Y | Y | N | Halazepam
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 0.76000 | Diazepam
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 865 | N | N | N | Kainic acid hydrate
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0.33333 | Proline
| 0.015453 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
| 866 | N | N | Y | Pentobarbital calcium
| GABRE | 0.40000 | Pentobarbital
| 0.33697 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 867 | N | N | N | Sertraline
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.42308 | Ketamine hydrochloride
| 0.010907 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 868 | N | N | N | Gallopamil hydrochloride
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.86486 | Verapamil
| 0.010388 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 869 | N | N | N | Fluoxetine hydrochloride
| KCNJ9: potassium inwardly-rectifying channel, subfamily J, member 9 | 0.33333 | Verapamil
| 0.68294 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 870 | N | N | N | Thioridazine hydrochloride
| KCNJ9: potassium inwardly-rectifying channel, subfamily J, member 9 | 0.34091 | Verapamil
| 0.68294 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 871 | N | N | N | Indapamide
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.41026 | Glipizide
| 0.027394 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 872 | N | N | N | Flecainide acetate
| GLRA1: glycine receptor, alpha 1 | 0.25714 | Sevoflurane
| 0.019946 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 873 | N | N | N | Gabapentin
| ACCN1: amiloride-sensitive cation channel 1, neuronal | 0.034483 | Amiloride hydrochloride
| 0.48895 | ACCN3: amiloride-sensitive cation channel 3 |
| 874 | N | N | N | Methohexital
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 0.59091 | Pentobarbital
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 875 | N | N | N | Glyclopyramide
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.37838 | Cisapride
| 0.014705 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 876 | N | N | N | Repaglinide
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.50000 | Moricizine
| 0.0099976 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 877 | N | N | N | Mibefradil dihydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.44898 | Verapamil
| 0.13545 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 878 | N | N | N | Promethazine teoclate
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.016138 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 879 | N | N | N | Codeine
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.25000 | Nicotine
| 0.44784 | CHRNA2 |
| 880 | N | N | N | Promethazine hydrochloride
| KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | 0.39024 | Dequalinium chloride
| 0.55275 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 881 | N | N | N | Hydroflumethiazide
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.45833 | Riluzole
| 0.0091408 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 882 | N | N | N | Bupivacaine hydrochloride
| KCND1: potassium voltage-gated channel, Shal-related subfamily, member 1 | 0.19355 | Diazoxide
| 0.62617 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 883 | N | N | N | Halazepam
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.48387 | Fluoxetine
| 0.016138 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 884 | N | N | N | Diltiazem malate
| KCNC3: potassium voltage-gated channel, Shaw-related subfamily, member 3 | 0.33962 | Verapamil
| 0.57702 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 885 | N | N | N | Nifedipine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.38235 | Cocaine
| 0.13474 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 886 | N | N | N | Caffeine
| CLCN2: chloride channel 2 | 0.051282 | Lubiprostone
| 0.013935 | P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 |
| 887 | N | N | N | Trichlormethiazide
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.40000 | Riluzole
| 0.0091408 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 888 | N | Y | N | Verapamil hydrochloride
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.97059 | Verapamil
| 0.10064 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 889 | N | N | N | Trifluoperazine hydrochloride
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.32353 | Riluzole
| 0.018721 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 890 | N | N | N | Rocuronium bromide
 | CHRNA4: cholinergic receptor, nicotinic, alpha 4 | 0.22368 | Codeine sulfate
| 0.52847 | CHRNA2 |
| 891 | N | N | N | Trimipramine
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.60714 | Profenamine hydrochloride
| 0.010907 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 892 | N | N | N | Thioridazine
| KCNJ9: potassium inwardly-rectifying channel, subfamily J, member 9 | 0.34884 | Verapamil
| 0.68294 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 893 | N | N | N | Amiloride hydrochloride
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.26923 | Riluzole
| 0.014175 | MCOLN1: mucolipin 1 |
| 894 | N | N | N | Gallopamil hydrochloride
| KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 | 0.86486 | Verapamil
| 0.025006 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 895 | Y | N | N | Tubocurarine chloride
| GABRD: gamma-aminobutyric acid (GABA) A receptor, delta | 0.23975 | Midazolam
| 0.29568 | GABRA5: gamma-aminobutyric acid (GABA) A receptor, alpha 5 |
| 896 | N | N | N | Felbamate
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.45000 | Benzocaine
| 0.010173 | GLRA2: glycine receptor, alpha 2 |
| 897 | N | N | N | Loratadine
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.32558 | Diltiazem hydrochloride
| 0.55487 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 898 | N | N | N | Caffeine
| MCOLN1: mucolipin 1 | 0.14286 | Amiloride hydrochloride
| 0.023510 | P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 |
| 899 | N | N | N | Bupivacaine hydrochloride
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.41935 | Tolazamide
| 0.39592 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 900 | N | N | N | Kainic acid hydrate
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0.33333 | Proline
| 0.012768 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
| 901 | N | N | N | Promethazine teoclate
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.40476 | Caffeine and sodium benzoate
| 0.31077 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 902 | N | N | N | Methyclothiazide
 | GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.57143 | Cyclothiazide
| 0.010212 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 903 | N | N | N | Caffeine
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.14286 | Amiloride hydrochloride
| 0.016201 | P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 |
| 904 | N | N | N | Diazoxide
| P2RX3: purinergic receptor P2X, ligand-gated ion channel, 3 | 0.21739 | Caffeine
| 0.030341 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 905 | N | N | N | Gallopamil hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.86486 | Verapamil
| 0.11951 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 906 | N | Y | N | Verapamil hydrochloride
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.97059 | Verapamil
| 0.13350 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 907 | N | N | N | Penicillin G procaine
| GABRG3 | 0.38776 | Flurazepam
| 0.40101 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 908 | N | N | N | Procainamide hydrochloride
| CHRND: cholinergic receptor, nicotinic, delta | 0.72727 | Metoclopramide
| 0.012164 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 909 | N | N | N | Aminoglutethimide
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.42105 | Ethosuximide
| 0.0080876 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 910 | N | N | N | Diazoxide
| P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 | 0.21739 | Caffeine
| 0.029220 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 911 | N | N | N | Amiodarone hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.45000 | Propafenone hydrochloride
| 0.51877 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 912 | N | N | N | Halazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38461 | Diltiazem hydrochloride
| 0.019068 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 913 | N | N | N | Mepivacaine hydrochloride
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.75000 | Bupivacaine hydrochloride
| 0.027135 | KCNK5: potassium channel, subfamily K, member 5 |
| 914 | N | N | N | Trichlormethiazide
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.36667 | Furosemide
| 0.011447 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 915 | N | N | N | Riluzole
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.26923 | Amiloride hydrochloride
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 916 | N | N | N | Benzocaine
| KCNK5: potassium channel, subfamily K, member 5 | 0.57895 | Procaine hydrochloride
| 0.025338 | SCN4B |
| 917 | N | N | N | Azimilide dihydrochloride
| KCNE1: potassium voltage-gated channel, Isk-related family, member 1 | 0.21818 | Verapamil
| 0.026945 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 918 | N | N | N | Flurazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.46154 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 919 | N | N | N | Procainamide hydrochloride
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.72727 | Metoclopramide
| 0.013618 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 920 | N | N | N | Fluoxetine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.46875 | Halazepam
| 0.021675 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 921 | N | N | N | Enoxacin hydrate
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.30682 | Trifluoperazine maleate
| 0.021832 | GABRA3: gamma-aminobutyric acid (GABA) A receptor, alpha 3 |
| 922 | N | N | N | Codeine phosphate
 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.16176 | Exemestane
| 0.44784 | CHRNA2 |
| 923 | N | Y | N | Primidone
| GABRA5: gamma-aminobutyric acid (GABA) A receptor, alpha 5 | 0.43478 | Ketamine hydrochloride
| 0.69495 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 924 | N | N | N | Enoxacin hydrate
| GABRG3 | 0.22500 | Flurazepam
| 0.40101 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 925 | N | N | N | Quinine hydrochloride hydrate
| KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 | 0.31250 | Ketoconazole
| 0.53242 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 926 | N | N | N | Oxcarbazepine
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.53846 | Desipramine hydrochloride
| 0.011391 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 927 | N | N | N | Diazoxide
| P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 | 0.21739 | Caffeine
| 0.045455 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 928 | N | N | N | Amiodarone hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.42105 | Fluoxetine
| 0.027535 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 929 | N | N | N | Verapamil
| GRIN2D: glutamate receptor, ionotropic, N-methyl D-aspartate 2D | 0.28261 | Haloperidol
| 0.029109 | KCNK4: potassium channel, subfamily K, member 4 |
| 930 | N | N | N | Mazindol
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0.076923 | Proline
| 0.41013 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 931 | N | Y | Y | Clobazam
| GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 | 0.78261 | Diazepam
| 0.74880 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 932 | N | N | N | Ibutilide fumarate
| KCNK5: potassium channel, subfamily K, member 5 | 0.29167 | Verapamil
| 0.17161 | KCNK1: potassium channel, subfamily K, member 1 |
| 933 | N | N | N | Ethotoin
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.36000 | Phenytoin
| 0.58238 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 934 | N | N | N | Trifluoperazine hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.60526 | Moricizine hydrochloride
| 0.0087397 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 935 | N | N | N | Bepridil hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.47059 | Desipramine hydrochloride
| 0.035737 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
| 936 | N | N | N | Doxorubicin hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.30508 | Quinidine gluconate
| 0.0051579 | RYR1: ryanodine receptor 1 (skeletal) |
| 937 | N | N | N | Diazoxide
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.29167 | Ketamine hydrochloride
| 0.094588 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 938 | N | N | N | Phencyclidine hydrochloride
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.44444 | Dextromethorphan
| 0.015803 | CHRNA10 |
| 939 | N | N | N | Propafenone hydrochloride
| KCNK16: potassium channel, subfamily K, member 16 | 0.34091 | Verapamil
| 0.24672 | KCNK5: potassium channel, subfamily K, member 5 |
| 940 | N | N | N | Indapamide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.43333 | Glyclopyramide
| 0.029070 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 941 | N | N | N | Astemizole
| KCNH6: potassium voltage-gated channel, subfamily H (eag-related), member 6 | 0.28846 | Verapamil
| 0.50037 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 942 | N | N | N | Loratadine
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.56250 | Clozapine
| 0.017228 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 943 | Y | N | Y | Cocaine
| SCN2A: sodium channel, voltage-gated, type II, alpha subunit | 0.33333 | Procaine hydrochloride
| 0.60832 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 944 | N | N | N | Gabapentin
| ACCN2: amiloride-sensitive cation channel 2, neuronal | 0.034483 | Amiloride hydrochloride
| 0.47336 | ACCN3: amiloride-sensitive cation channel 3 |
| 945 | N | N | N | Codeine
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.38889 | Quinine hydrochloride hydrate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 946 | N | N | N | Penicillin G procaine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.40476 | Procaine hydrochloride
| 0.011567 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 947 | N | N | N | Pramoxine hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.42105 | Cisapride
| 0.019783 | KCNK5: potassium channel, subfamily K, member 5 |
| 948 | N | N | N | Thioridazine
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.53333 | Maprotiline
| 0.020826 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 949 | N | N | N | Codeine
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.35294 | Granisetron
| 0.26265 | CHRNA10 |
| 950 | N | N | Y | Tocainide
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.93333 | Tocainide hydrochloride
| 0.58865 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 951 | N | N | N | Ketoconazole
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.37500 | Trifluoperazine hydrochloride
| 0.34677 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 952 | N | N | N | Verapamil hydrochloride
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.97059 | Verapamil
| 0.10383 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 953 | N | N | N | Cetiedil citrate
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.31707 | Methylphenidate
| 0.022059 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 954 | N | N | N | Quinine sulfate
| CHRNA2 | 0.39744 | Codeine sulfate
| 0.017256 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 955 | Y | N | N | Glyburide
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.45652 | Astemizole
| 0.015300 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 956 | N | N | N | Dofetilide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.41270 | Ibutilide fumarate
| 0.025318 | KCNK2: potassium channel, subfamily K, member 2 |
| 957 | N | N | N | Desflurane
| GABRA3: gamma-aminobutyric acid (GABA) A receptor, alpha 3 | 1 | Isoflurane
| 0.66731 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 958 | N | N | N | Bupivacaine hydrochloride
| KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.34146 | Flecainide acetate
| 0.22153 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 959 | N | N | N | Verapamil hydrochloride
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.97059 | Verapamil
| 0.24349 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 960 | N | N | N | Pramoxine hydrochloride
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.25714 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 961 | N | N | N | Biperiden
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.34615 | Nicotine
| 0.44784 | CHRNA2 |
| 962 | N | N | N | Hydrochlorothiazide
 | GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.64000 | Cyclothiazide
| 0.010212 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 963 | N | N | N | Halazepam
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.41667 | Bendroflumethiazide
| 0.011447 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 964 | N | N | N | Amiloride hydrochloride
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.36000 | Lamotrigine
| 0.12915 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 965 | N | N | N | Tolbutamide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.45833 | Lidocaine
| 0.010834 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 966 | N | N | N | Pramoxine hydrochloride
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.30769 | Benzocaine
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 967 | N | N | N | Dibucaine
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.40476 | Halofantrine hydrochloride
| 0.0091581 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 968 | N | N | N | Ethotoin
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.52381 | Aminoglutethimide
| 0.0091480 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 969 | N | N | N | Amiodarone hydrochloride
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38298 | Verapamil
| 0.59825 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 970 | N | N | N | Quinine sulfate
| SCN1A: sodium channel, voltage-gated, type I, alpha subunit | 1 | Quinidine sulfate
| 0.020008 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 |
| 971 | N | N | N | Galantamine hydrobromide
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36111 | Quinine hydrochloride hydrate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 972 | N | N | N | Pentobarbital
| GLRA3 | 0.027027 | Tropisetron hydrochloride
| 0.32591 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 973 | N | N | N | Glyclopyramide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.32000 | Diazoxide
| 0.0097843 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 974 | N | N | N | Dantrolene
| KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 | 0.50000 | Azimilide dihydrochloride
| 0.0059674 | RYR1: ryanodine receptor 1 (skeletal) |
| 975 | N | N | N | Rocuronium bromide
| CHRNA3: cholinergic receptor, nicotinic, alpha 3 | 0.22368 | Codeine sulfate
| 0.52424 | CHRNA2 |
| 976 | N | N | N | Verapamil
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.28261 | Haloperidol
| 0.026014 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 977 | N | N | N | Zonisamide
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.29167 | Felbamate
| 0.022827 | SCN4B |
| 978 | N | N | N | Carbamazepine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.37037 | Phenytoin
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 979 | N | N | N | Dizocilpine maleate
| KCNJ9: potassium inwardly-rectifying channel, subfamily J, member 9 | 0.23404 | Verapamil
| 0.68294 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 980 | N | N | N | Dibucaine
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.17500 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 981 | N | N | N | Caffeine
| KCNK12: potassium channel, subfamily K, member 12 | 0 | Halothane
| 0.019268 | P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 |
| 982 | Y | N | N | Prilocaine
| SCN8A: sodium channel, voltage gated, type VIII, alpha subunit | 0.94118 | Prilocaine hydrochloride
| 0.58865 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 983 | N | N | N | Ketamine hydrochloride
| GLRA1: glycine receptor, alpha 1 | 0.39286 | Tropisetron hydrochloride
| 0.32784 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 984 | N | N | Y | Benzocaine
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.57895 | Procaine hydrochloride
| 0.75410 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 985 | N | N | N | Dextromethorphan
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.35484 | Cocaine
| 0.41406 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 986 | N | N | N | Gallopamil hydrochloride
| CHRNA2 | 0.36508 | Metocurine iodide
| 0.010362 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 987 | N | N | N | Chloroprocaine hydrochloride
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.28125 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 988 | N | N | N | Nateglinide
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.48387 | Granisetron
| 0.017658 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 989 | N | N | N | Primidone
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.57143 | Aminoglutethimide
| 0.090264 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 990 | N | N | N | Amiloride hydrochloride
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.36000 | Lamotrigine
| 0.11479 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 991 | N | N | N | Glimepiride
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.55814 | Glyburide
| 0.014445 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 992 | N | N | N | Biperiden
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.36364 | Cocaine
| 0.020712 | CHRNA2 |
| 993 | N | N | N | Benzocaine
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.36000 | Cocaine
| 0.47691 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 994 | N | N | N | Maprotiline
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.51852 | Mirtazapine
| 0.018814 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 995 | N | N | N | Proparacaine hydrochloride
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.36000 | Benzocaine
| 0.48453 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 996 | N | N | N | Kainic acid hydrate
| CLCN2: chloride channel 2 | 0.22857 | Lubiprostone
| 0.012355 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
| 997 | N | N | N | Prilocaine
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.47826 | Tolbutamide
| 0.0099976 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 998 | N | N | Y | Tocainide
| SCN9A: sodium channel, voltage-gated, type IX, alpha subunit | 0.93333 | Tocainide hydrochloride
| 0.59648 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 999 | N | N | N | Gallopamil hydrochloride
| KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.86486 | Verapamil
| 0.025943 | CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit |
| 1000 | N | N | N | Sertraline
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.53571 | Clozapine
| 0.013198 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |